0001562762-23-000132 | 10-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Document Type	10-K
Entity Central Index Key	0001851657
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-41058
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	505 Odyssey Way
Entity Address, City or Town	Merritt Island
Entity Address, Postal Zip Code	32953
Entity Address, State or Province	FL
Entity Tax Identification Number	86-2083865
Entity Registrant Name	VAXXINITY, INC.
Entity Ex Transition Period	false
Auditor Name	Armanino LLP
Auditor Firm ID	32
Local Phone Number	244-5739
City Area Code	254
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
ICFR Auditor Attestation Flag	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Public Float			$ 94.5
Documents Incorporated by Reference	Portions of the following document are incorporated by reference in Part III of this Report: the registrant’s definitive proxy statement relating to its 2023 Annual Meeting of Shareholders. We currently anticipate that our definitive proxy statement will be filed with the SEC no later than 120 days after December 31, 2022 , pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended.
Entity Shell Company	false
Auditor Location	San Ramon, California
Document Annual Report	true
Class A Common Stock [Member]
Entity Common Stock, Shares Outstanding		112,188,911
Common Class B [Member]
Entity Common Stock, Shares Outstanding		13,874,132

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 33,475	$ 144,885
Short-term investments	53,352	0
Restricted cash	1,095	172
Amounts due from related parties	414	393
Prepaid expenses and other current assets	5,551	8,851
Total current assets	93,887	154,301
Property and equipment, net	12,512	12,372
Total assets	106,399	166,673
Current liabilities:
Accounts payable	5,295	3,192
Amounts due to related parties	12,772	19,407
Accrued expenses and other current liabilities	11,370	4,519
Notes payable	391	376
Notes payable to related party	1,113	0
Total current liabilities	30,941	27,494
Other liabilities:
Notes payable, net of current portion	9,933	10,323
Notes payable to related party, net of current portion	3,112	0
Other long-term liabilities	236	237
Total liabilities	44,222	38,054
Commitments and contingencies (Note 17)
Preferred stock: $0.0001 par value, 50,000,000 shares authorized at December 31, 2022 and 2021	0	0
Stockholders equity:
Additional paid-in capital	366,799	357,822
Accumulated other comprehensive income (loss)	(197)	0
Accumulated deficit	(304,703)	(229,481)
Total stockholders' equity	62,177	128,619
Total liabilities and stockholders' equity	106,399	166,673
Class A Common Stock [Member]
Stockholders equity:
Common stock:	278	278
Common Class B [Member]
Stockholders equity:
Common stock:	$ 0	$ 0

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated	50,000,000	50,000,000
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	112,182,750	111,518,094
Common stock, shares outstanding	112,182,750	111,518,094
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,874,132	13,874,132
Common stock, shares outstanding	13,874,132	13,874,132

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Income [Abstract]
Revenue	$ 0	$ 66
Cost of revenue	0	1,937
Gross (loss) profit	0	(1,871)
Operating expenses:
Research and development	47,627	71,379
General and administrative	28,352	51,825
Total operating expenses	75,979	123,204
Loss from operations	(75,979)	(125,075)
Other (income) expense:
Interest and other expense	514	840
Interest and other income	(1,259)	(9)
Change in fair value of convertible notes	0	2,667
Change in fair value of simple agreement for future equity	0	8,365
Change in fair value of warrant liability	0	214
(Gain) loss on foreign currency translation, net	(12)	23
Other (income) expense	(757)	12,100
Loss before income taxes	(75,222)	(137,175)
Provision for income taxes	0	0
Net loss	$ (75,222)	$ (137,175)
Net loss per share, basic	$ (0.60)	$ (1.79)
Net loss per share, diluted	$ (0.60)	$ (1.79)
Weighted average common shares outstanding, basic	125,939,050	76,586,842
Weighted average common shares outstanding, diluted	125,939,050	76,586,842
Other comprehensive loss:
Unrealized loss (gain) on investments	$ 197	$ 0
Other comprehensive loss	$ 197	$ 0

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Preferred Stock [Member] Series Seed Stock [Member]	Preferred Stock [Member] Series Seed-1 Stock [Member]	Preferred Stock [Member] Series Seed-2 Stock [Member]	Preferred Stock [Member] Series A-1 Stock [Member]	Preferred Stock [Member] Series A-2 Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] SAFEs [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Debt [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Notes Payable, Related Parties [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member] Conversion To Class A Common Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ (87,375)			$ 272		$ 62,475		$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0						$ 0		$ (23)	$ 4,682		$ (92,306)
Beginning balance, common shares at Dec. 31, 2020				60,360,523	10,999,149
Beginning balance, preferred shares at Dec. 31, 2020								7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0						0
Beginning balance, treasury shares at Dec. 31, 2020																					(3,169,093)
Issuance of common stock upon exercise of stock options, shares				186,202
Issuance of common stock upon exercise of stock options	170																					170
Issuance of stock, shares				6,537,711															15,365,574
Issuance of stock	71,077			$ 1															$ 122,791			71,076
Exchange of preferred stock, shares								(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock								$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares														4,539,060	134,106	(62,223,095)	3,624,114	423,230		(15,365,574)
Conversion of stock							$ (251,230)							$ 35,600	$ 614	$ (128,439)	$ 27,545	$ 2,205		$ (122,791)
Exercise of warrants, shares				112,373
Exercise of warrants	177																					177
Vesting of restricted stock, shares				15,405
Issuance of common stock upon stock grant, shares				485,836
Issuance of common stock upon stock grant	103																					103
Retirement of treasury stock upon reorganization, shares				3,169,093																	3,169,093
Retirement of treasury stock upon reorganization																					$ 23	(23)
Stock-based compensation expense	30,412																					30,412
Reclassification of common stock to Class A, shares				49,864,120
Reclassification of common stock to Class A	251,230			$ 5																		251,225
Reclassification of common stock to Class B, shares				2,874,983	2,874,983
Net loss	(137,175)																							(137,175)
Ending balance at Dec. 31, 2021	$ 128,619			$ 278		$ 0		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0						$ 0		$ 0	357,822	$ 0	(229,481)
Ending balance, common shares at Dec. 31, 2021		111,518,094	13,874,132	111,518,094	13,874,132
Ending balance, preferred shares at Dec. 31, 2021	0							0	0	0	0	0	0						0
Ending balance, treasury shares at Dec. 31, 2021																					0
Issuance of common stock upon exercise of stock options, shares	1,066,586			664,656
Issuance of common stock upon exercise of stock options	$ 263																					263
Issuance of stock, shares	32,505,306	6,000,000
Stock-based compensation expense	$ 8,714																					8,714
Unrealized loss on investments	(197)																						(197)
Net loss	(75,222)																							(75,222)
Ending balance at Dec. 31, 2022	$ 62,177			$ 278																		$ 366,799	$ (197)	$ (304,703)
Ending balance, common shares at Dec. 31, 2022		112,182,750	13,874,132	112,182,750	13,874,132
Ending balance, preferred shares at Dec. 31, 2022	0

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	Dec. 31, 2021 USD ($)
Offering expenses	$ 13,913
Series B Preferred Stock [Member]
Issuance of stock, issuance costs	$ 133

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (75,222)	$ (137,175)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,684	1,102
Amortization of debt issuance costs	53	261
Amortization of discount on short-term investments	(1,022)	0
Stock-based compensation expense	8,714	30,412
Non-cash consulting expense	0	280
Non-cash loss on disposal	43
Change in fair value of convertible notes	0	2,667
Change in fair value of warrant liability	0	214
Change in fair value of simple agreement for future equity	0	8,365
Change in operating assets and liabilities:
Accounts receivable	0	26
Amounts due from related parties	(21)	(31)
Prepaid expenses and other current assets	3,300	(4,704)
Deferred offering costs	0	2,254
Accounts payable	2,103	2,174
Amounts due to related parties	(2,410)	11,402
Accrued expenses and other current liabilities	6,851	1,775
Other long-term liabilities	(1)	(12)
Net cash used in operating activities	(55,928)	(80,990)
Cash flows from investing activities:
Purchase of short-term investments	(107,526)	0
Redemption of short-term investments	55,000	0
Purchase of property and equipment	(1,866)	(1,318)
Net cash used in investing activities	(54,392)	(1,318)
Cash flows from financing activities:
Proceeds from initial public offering, net of offering expenses of $13,913	0	71,077
Proceeds from issuance of convertible note payable	0	2,000
Repayment of convertible notes	0	(2,000)
Repayments of note payable with related party	(430)	(414)
Proceeds from issuance of Series B convertible preferred stock, net of issuances costs	0	122,791
Repayments Of Medium Term Notes	0	100
Proceeds from issuance of simple agreement for future equity	0	2,900
Repayment from Paycheck Protection Program	0	(257)
Proceeds from exercise of stock options	263	170
Net cash (used in) provided by financing activities	(167)	196,167
Change in cash, cash equivalents, and restricted cash	(110,487)	113,859
Cash, cash equivalents and restricted cash at beginning of period	145,057	31,198
Cash, cash equivalents and restricted cash at end of period	34,570	145,057
Supplemental Disclosure
Cash paid for interest	367	581
Noncash Financing Activities
Retirement Of Treasury Shares	0	23
Simple Agreement for Future Equity [Member]
Conversion Of Stock Amount Issued 1	0	35,600
Related Party Into Note Payable [Member]
Conversion Of Stock Amount Issued 1	4,225	0
Series A and Series B to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	0	251,230
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A [Member]
Conversion Of Stock Amount Issued 1	0	62,475
Convertible Notes Payable to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	0	27,545
Notes into Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	0	2,205
Warrant to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	0	614
Warrant to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	$ 0	$ 177

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Consolidated Statements of Cash Flows [Abstract]
Offering Costs	$ 13,913

Nature of the Business	12 Months Ended
Nature of the Business	Dec. 31, 2022
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, Inc., a Delaware corporation (“Vaxxinity ,” and together with its subsidiaries, the “Company”), was formed through the combination of two separate businesses that originated from United Biomedical, Inc. (“UBI”) in two separate transactions: a spin-out from UBI in 2014 of operations focused on developing chronic disease product candidates that resulted in United Neuroscience (“UNS”), and a second spin-out from UBI in 2020 of operations focused on the development of a COVID-19 vaccine that resulted in C19 Corp. (“COVAXX”). On February 2, 2021, Vaxxinity was incorporated for the purpose of reorganizing and combining UNS and COVAXX and on March 2, 2021, did so by acquiring all of the outstanding equity interests of UNS and COVAXX pursuant to a contribution and exchange agreement (the “Contribution and Exchange Agreement”) whereby the existing equity holders of UNS and COVAXX contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity (the “Reorganization”). The Company is a biotechnology company currently focused on developing product candidates for human use in the fields of neurology, pain, cardiovascular diseases and coronaviruses utilizing its “Vaxxine Platform”—a synthetic peptide vaccine technology first developed by UBI and subsequently refined over the last two decades. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic diseases with large global unmet medical need. The Company is also developing a heterologous booster vaccine for SARS-Cov-2. UBI is a significant shareholder of the Company and, therefore, considered a related party. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company’s product candidates are in development and will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance -reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees and consultants. Contribution and Exchange Agreement On March 2, 2021, in accordance with the Contribution and Exchange Agreement, (i) all outstanding shares of UNS and COVAXX preferred stock and common stock were contributed to Vaxxinity and exchanged for like shares of stock in Vaxxinity, (ii) the outstanding options to purchase shares of UNS and COVAXX common stock were terminated and substituted with options to purchase shares of common stock in Vaxxinity, (iii) the outstanding warrant to purchase shares of COVAXX common stock was cancelled and exchanged for a warrant to acquire common stock in Vaxxinity and (iv) each outstanding Reorganization Convertible Note (as defined below) was contributed to Vaxxinity and the holders of such notes received Series A preferred stock in Vaxxini ty. In particular: • Each UNS common share and convertible preferred share was exchanged for 0.2191 shares of Vaxxinity common stock or Series A preferred stock, as applicable; • Each share of COVAXX common and convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity common stock or Series A preferred stock, as applicable (and prior to the closing of the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of Vaxxinity’s Series A preferred stock); • The Reorganization Convertible Notes were exchanged for an aggregate of 4,047,344 shares of Vaxxinity’s Series A preferred stock; and • Each outstanding option of both UNS and COVAXX to purchase common shares of UNS or COVAXX was terminated and substituted with an option to purchase shares of Class A common stock of Vaxxinity. Each outstanding UNS option was exchanged based on a conversion ratio of 0.2191 . Each outstanding COVAXX option was exchanged based on a conversion ratio of 3.4233 . All parties to the Contribution and Exchange Agreement intend that the contribution of outstanding equity interests to Vaxxinity in exchange for Vaxxinity’s common stock and preferred stock will be treated as an integrated transaction for U.S. federal income tax purposes that is governed by Section 351(a) of the Internal Revenue Code of 1986, as amended. The Reorganization was determined to be a common control transaction, so the carrying values of all contributed assets and assumed liabilities remained unchanged and the financial information for all periods in the financial statements presented prior to the Reorganization are presented on a consolidated basis. Reverse Stock Split On October 29, 2021, the Company effectuated a reverse stock split of 1-for- 1.556 (the “Stock Split”) of the Company’s Class A and Class B common stock pursuant to an amendment to the Company’s Amended and Restated Certificate of Incorporation approved by the Company’s board of directors and stockholders. As a result of the Stock Split, the Company also adjusted the share and per share amounts associated with its options and warrants to purchase shares of its common stock. These consolidated financial statements including the notes have been retroactively adjusted to reflect the Stock Split for all periods presented. Any fractional shares that would have resulted from the Stock Split have been rounded down to the nearest whole share. Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 shares of Class A common stock at a public offering price of $ 13.00 per share. On November 18, 2021 the Company held a subsequent closing for the issuance of an additional 537,711 shares of Class A common stock pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of Class A common stock at the IPO price, less underwriting discounts and commissions. The aggregate net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, was approximately $ 71.1 million. Upon the closing of the IPO, all previously outstanding shares of the Company’s redeemable convertible preferred stock were automatically converted at the same ratio used for the Stock Split (1-for- 1.556 ) into shares of its Class A common stock. Liquidity As of December 31, 2022, the Company had $ 87.9 million of highly liquid assets to fund operations, including $ 33.5 million of cash and cash equivalents, $ 53.4 million of short-term investments, and a $ 1.1 million restricted cash balance of which $ 1.0 million is restricted for the reimbursement of certain research and development expenses related to our UB-612 COVID-19 vaccine program. To date, the Company has primarily financed its operations through the sale of convertible preferred stock and common stock, borrowings under promissory notes (including Convertible Notes), a portion of which has been raised from related party entities, and grants from foundations such as the Coalition of Epidemic Preparedness Innovations (CEPI) and the Michael J. Fox Foundation (MJFF). The Company has experienced significant negative cash flows from operations since inception, and incurred a net loss of $ 75.2 million for the year ended December 31, 2022. Net cash used in operating activities for the year ended December 31, 2022 was $ 55.9 million. In addition, as of December 31, 2022, the Company has an accumulated deficit of $ 304.7 million. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. As of the date these financial statements were available to be issued, the Company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. Unless and until the Company is able to obtain regulatory approval for, and generate significant revenues from commercialization of our product candidates, the Company will need to seek additional capital in order to continue to fund future research and development activities. This may occur through strategic alliances, licensing arrangements, grants and/or future public or private debt or equity financings. Additional funding may not be available on terms the Company finds acceptable or at all. If the Company is unable to obtain sufficient capital to continue to advance its programs, the Company would be forced to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that the Company would otherwise prefer to develop and market itself. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Impact of COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a COVID-19 pandemic. The COVID-19 pandemic is evolving, and to date, has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. While the pandemic has significantly subsided since 2020, the Company continues to monitor how COVID-19 outbreaks associated with new variants impact all aspects of its business, including our operations and the operations of its customers, suppliers, vendors and business partners. The extent to which COVID-19 impacts the Company’s business, results of operation and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. If the Company or any of the third parties with whom the Company engages, however, were to experience shutdowns or other business disruptions, its ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on its business, results of operation and financial condition. The Company has not incurred impairment losses in the carrying values of its assets as a result of the COVID-19 pandemic and the Company is not aware of any specific related event or circumstance that would require it to revise estimates reflected in these consolidated financial statements.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term 2. Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial reporting. The consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement and the Stock Split ratio. Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Income statement accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency (losses) gains in the consolidated statements of operations. Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment. Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common stock and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, prepaid expense recognition, income tax valuation allowance and the accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions. Related party transactions The Company has a policy governing related party transactions that defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Audit Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Audit Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return. Restricted cash As of December 31, 2022 and 2021 a deposit of $ 1.1 million and $ 0.2 million, respectively, was restricted from withdrawal. These restrictions related to cash payments received in advance under the CEPI Funding Agreement and securing credit card obligations as of December 31, 2022 and securing credit card obligations as of December 31, 2021. These balances are included in restricted cash on the accompanying consolidated balance sheets. Short Term Investments The Company determines the appropriate classification of its investments at the time of purchase. Currently, all of the Company’s investments are classified as available-for-sale in accordance with ASC Topic 320. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income or loss. Realized gains and losses, interest income earned on the Company’s cash, cash equivalents and investments, and amortization or accretion of discounts and premiums on investments are included within other income (expense) on the accompanying consolidated statements of operations. Available-for-sale debt securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported within equity as accumulated other comprehensive income on the accompanying consolidated statement of stockholder’s equity (deficit). The Company did no t record any such impairments during the year ended December 31, 2022 and 2021. Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in money market accounts. The Company maintains each of its cash balances with high- quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers. Leases At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in Operating lease right-of-use assets and Operating lease liabilities in our consolidated balance sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. The Company has elected to apply the practical short-term expedient to leases with a lease term of 12 months or less, which does not subject the leases to capitalization. Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred . Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets. Deferred offering costs The Company capitalizes certain legal, audit, accounting and other third-party fees that are directly associated with an in-process capital financing effort as deferred offering costs until such financing is consummated. After consummation of the financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the financing. Should the financing be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the accompanying consolidated statements of operations. Fair value measurements Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Prior to the conversion in accordance with the Contribution and Exchange Agreement, the majority of the Company’s convertible notes and all of the simple agreement for future equity (“SAFE”) and warrant liabilities were carried at fair value and were classified as Level 3 liabilities. Convertible notes payable The Company issued convertible notes payable at various times from 2014 to 2021. The Company accounts for the convertible notes payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are accounted for as straight debt under ASC 470, Debt (“ASC 470”). The Company has elected to separate interest expense from the full change in fair value of the convertible notes. Debt issuance costs incurred by the Company are amortized to interest expense over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations. On March 2, 2021, each convertible note that was outstanding was exchanged for shares of Series A preferred stock (see Note 9). Debt issuance costs The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statements of operations. Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, each SAFE that was outstanding was converted into shares of the Company’s Series A preferred stock (see Note 12). Classification of convertible preferred stock The Company records all convertible preferred stock at its original issuance price, less direct and incremental issuance costs, as stipulated by its terms. The Company’s convertible preferred stock is classified outside of stockholders’ deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. All shares of the Company’s Series A and Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering (see Note 11). Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. The Company applies ASC 606 to contracts with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by evaluating whether each promised good or service is distinct. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services, the intended benefit of the contract and whether each good or service is separately identifiable from the other aspects of the contractual relationship. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the transaction price to be constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and, if over time, recognition is based on the use of an output or input method. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer. Coalition for Epidemic Preparedness (“CEPI”) grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI has agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in early 2022, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. Cash payments received in advance under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. As funds are received they are included within restricted cash offset by a corresponding short-term accrued liability. The Company recognizes payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. Taiwan Centers for Disease Control grant United Biomedical, Inc., Asia (“UBI-Asia”), a related party through common ownership which is responsible for applying for and managing grants on the Company’s behalf, was awarded a grant by the Taiwan Centers for Disease Control (“Taiwan CDC”) for COVID-19 vaccine development. UBI-Asia contracted with the Company to conduct a two-phase clinical trial of a COVID-19 vaccine candidate in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as defined in the agreement. At each reporting date, the Company assesses the status of all the activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the Taiwan CDC to reimburse costs incurred on the clinical trials and not expected to be refunded back to the Taiwan CDC as contra research and development expenses in the accompanying consolidated statements of operations. Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 19). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model (“Black-Scholes”), which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. The Company, both prior to and after the IPO in November 2021, lacks sufficient company-specific historical and implied volatility information for its stock, and therefore estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The conditions present in the Company's grants contain both performance and market conditions. The effect of each condition is reflected in the grant-date fair value and the performance-based options are measured considering the probability of satisfying the performance and market conditions. The Company has used a Monte Carlo Simulation Model to calculate the fair value of the performance condition (the completion of the IPO) and market condition (the 25% higher value after the IPO condition). The performance condition was determined to not be probable at the time of the grant date, and the recognition of compensation cost was deferred until the IPO was consummated in November 2021. The recognition of expense for the portion of the grant-date fair value assigned to the market condition will be recognized as expense according to the derived service period in the valuation model. Income taxes The Company accounts for income taxes according to the ASC 740, Income Taxes (“ASC 740”) using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax positions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net loss per share Basic earnings per common share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income (loss) by the weighted- average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. For purpose of this calculation, outstanding options, unvested restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share if their effect is anti-dilutive. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive. Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, as long as the Company remains an EGC, it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs. Reclassifications The Company reclassified certain prepaid expenses from prepaid materials and supplies to clinical prepayments within the consolidated balance sheet to provide more current information on the components of this account. Prior year amounts have been reclassified to conform to the current year presentation. Additionally, certain expenses were reclassified between the research and development and general and administrative expenses within the consolidated statements of operations. These changes have no impact on our previously reported consolidated net loss, financial position or net increase in cash, cash equivalents, and restricted cash. Prior year amounts were not reclassified to conform to the current year presentation in the consolidated statements of operations. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018- 11provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company did not enter into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.

Short Term Investments	12 Months Ended
Short Term Investments	Dec. 31, 2022
Short Term Investments [Abstract]
Short Term Investments	3. Short Term Investments As of December 31, 2022, the Company’s short-term investments consist of the following (in thousands): As of December 31, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 53,549 $ (197) $ 53,352 Total $ 53,549 $ (197) $ 53,352

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	4. Fair Value Measurements The Company's money market accounts and short-term investments are shown at fair value based on unadjusted quoted market prices in active markets for identical assets. The value for the Convertible Notes, SAFE and warrant liability balances during 2021 were based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 the Convertible Notes, SAFEs and warrants were all converted into Series A preferred stock. The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): During the years ended December 31, 2022 and 2021, there were no transfers between Level 1, Level 2 and Level 3. Convertible Notes During the year ended December 31, 2021, the Company issued Convertible Notes. In accordance with ASC 480, a portion of the Convertible Notes were required to be measured and accounted for at fair value at each reporting date. The Company determined the Convertible Notes requiring a measurement to fair value represent a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs. Convertible Notes requiring a measurement to fair value are as follows (in thousands): The fair value of the Convertible Notes was estimated using a straight debt and conversion feature valuation model consisting of probability assumptions on multiple conversion scenarios, discount rates and interest rates. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the Convertible Notes were converted into Series A preferred stock. Simple Agreement for Future Equity—SAFE During the year ended December 31, 2021, the Company executed SAFE arrangements. The fair value of the SAFEs on the date of issuance was determined to equal the proceeds received by the Company. The value of the SAFEs on the date of conversion into preferred stock was determined to be equal to the fair value of the preferred stock issued, or $ 35.6 million during the year ended December 31, 2021. The following table sets forth a summary of the activities of the SAFE arrangements, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the SAFEs were converted into Series A preferred stock. Warrants to Purchase Series A-1 Convertible Preferred Stock & Common Stock In connection with the 2020 Series A-1 convertible preferred stock (“Series A-1 preferred”) financing transactions, the Company issued fully vested warrants to purchase 205,970 shares of Series A-1 preferred. The warrants were issued to advisors as consideration for assistance with the sale and issuance of the Series A-1 preferred. The warrants were determined to represent issuance costs and were recorded as a reduction in the proceeds received from the sale. The warrants were issued to advisors of the company and represented non-variable contingently redeemable instruments. As such, the warrants were accounted for as liabilities and adjusted to fair value at each reporting period. The warrants are exercisable on the date of issuance and have an exercise price of $ 0.003 per share and a contractual term of ten years . In December 2020, warrants were exercised for 71,862 shares of Series A-1 at $ 0.003 per share, resulting in cash proceeds of less than $ 1,000 . As of December 31, 2020, warrants to purchase 134,106 shares of Series A-1 preferred were outstanding. The Company continued to re-measure the fair value of the liability associated with the warrant to purchase shares of Series A-1 preferred at the end of each reporting period until the Reorganization, when the warrant converted into Series A preferred stock and subsequently, in connection with the IPO, converted into Class A common stock. The following table sets forth a summary of the activity of the warrant liability which represented a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 53,352 $ — $ — $ 53,352 Money market account 27,724 — — 27,724 Total assets $ 81,076 $ — $ — $ 81,076 Convertible Notes Balance at December 31, 2020 $ 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545) Balance at December 31, 2021 $ — SAFE Liability Balance at December 31, 2020 $ 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Balance at December 31, 2021 $ — Warrant Liability Balance at December 31, 2020 $ 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614) Balance at December 31, 2021 $ —

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): Clinical prepayments consisted of amounts paid in advance to clinical research organizations (“CROs”) for expenses related to our clinical trials, primarily UB-612, and included $ 1.9 million on deposit as of December 31, 2022 that will be credited against final UB- 612 trial expenses. The remaining clinical prepayment amounts are amortized to expense as earned by the CRO and clinical trial sites. Prepaid insurance consisted primarily of $ 1.6 million and $ 3.3 million for the unamortized portion of the Company’s annual D&O insurance fee as of December 31, 2022 and 2021, respectively. Prepaid materials and supplies consisted of amounts paid in advance related to the procurement and/or production of materials for use in the Company’s clinical trials, primarily UB-612. Amounts held by related parties totaled $ 0.2 million at December 31, 2022 and $ 3.5 million at December 31, 2021. Deposits consist of amounts held by the Company’s aircraft management company and the leaseholder for the Florida lab. Other prepaid expenses and current assets consist of various sales tax credits and receivables totaling $ 0.3 million and $ 0.3 million, as of December 31, 2022 and 2021, respectively and other prepaid expenses incurred in the normal course of business. December 31, 2022 2021 Clinical prepayments $ 2,679 $ 612 Prepaid insurance 1,870 3,510 Prepaid materials and supplies 248 3,517 Deposits 232 869 Other 522 343 $ 5,551 $ 8,851

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2022
Property and Equipment, Net [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Depreciation expense for the years ended December 31, 2022 and 2021 was $ 1.7 million and $ 1.1 million, respectively. December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 3,146 1,831 Leasehold improvements 403 — Software 415 168 Facilities, furniture and fixtures 37 85 Vehicles 87 87 Construction in progress 65 199 Total property and equipment 16,136 14,353 Less: accumulated depreciation (3,624) (1,981) Property and equipment, net $ 12,512 $ 12,372

Accrued Expenses and Other Current Liabilities	12 Months Ended
Accrued Expenses and Other Current Liabilities	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2022 2021 Accrued external research and development $ 6,904 $ 1,501 Accrued bonuses 2,568 2,294 Accrued professional fees and other 1,722 692 Accrued interest 176 32 $ 11,370 $ 4,519

Other Long-Term Liabilities	12 Months Ended
Other Long-Term Liabilities	Dec. 31, 2022
Other Liabilities [Abstract]
Other Long-Term Liabilities	8. Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): As of December 31, 2022 and 2021, approximately $ 0.2 million of the accrued tax provision relates to penalties and interest the Company may be subject to paying for late filing fees related to a foreign subsidiary. The Company expects these amounts to be forgiven but has accrued for them until the statute of limitations expires and it is appropriate to write them off. December 31, 2022 2021 Accrued tax provision $ 236 $ 236 Accrued rent — 1 $ 236 $ 237

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Dec. 31, 2022
Convertible Notes Payable [Abstract]
Convertible Notes Payable	9. Convertible Notes Payable Beginning in April 2018, the Company issued several Convertible Notes, some of which were issued to related parties. The Convertible Notes bore simple interest at annual rates ranging from 4.8 % to 6 %. All unpaid principal, together with the accrued interest thereon, were payable upon an event of default or upon maturity, which ranged from one to three years. The Convertible Notes contained a number of provisions addressing automatic and optional conversion, events of default, and prepayment provisions. The Company accounted for the Convertible Notes at fair value, in accordance with ASC 480, with any changes in fair value being included in other (income) expense, net in the accompanying statements of operations. In accordance with the Contribution and Exchange Agreement, on March 2, 2021 each Reorganization Convertible Note that was outstanding was exchanged for shares of Series A preferred stock, as set forth in the applicable Convertible Note agreements and the Contribution and Exchange Agreement. During the year ended December 31, 2021, the Company recognized interest expense of $ 0.2 million related to the Convertible Notes. In addition, during the year ended December 31, 2021, the Company recognized a change in fair value of $ 2.7 million in the accompanying consolidated statements of operations related to the Convertible Notes. The following table shows the activity of the Convertible Notes (in thousands): Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2020 $ 7,710 $ 10,510 $ 1,972 $ 3,848 $ 674 $ 183 $ (217) $ — $ 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2022
Notes Payable [Abstract]
Notes Payable	10. Notes Payable Notes Payable with Related Parties In December 2018, the Company entered into related party convertible notes payable (the “2018 Related Notes” and together with the Convertible Notes, the “Reorganization Convertible Notes”) for $ 2.0 million in aggregate proceeds, received in three tranches. The 2018 Related Notes bore simple interest at an annual rate of 5 % and contain a number of provisions addressing events of default and prepayment. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the 2018 Related Notes were converted into Series A preferred stock. During the year ended December 31, 2021, the Company recognized interest expense of less than $ 0.1 million on the 2018 Related Notes. 2019 Executive Note In November 2019, the Company borrowed $ 0.1 million from its Chief Executive Officer (the “2019 Executive Note”). No formal loan agreement was executed. However, the Company has elected to accrue interest at an annual rate of 5 %, consistent with the terms and conditions of the Convertible Notes and 2018 Related Notes, which was the closest benchmark the Company could evaluate. The 2019 Executive Note was repaid in August 2021. The activity of the 2018 Related Notes and 2019 Executive Note is as follows (in thousands): Note Payable—Airplane In connection with the acquisition of an airplane, the Company entered into a note payable agreement (the “2025 Note”) in June 2020 for $ 11.5 million, with an annual interest rate of 3.4 % and a maturity date of June 9, 2025. Principal and interest payments are payable monthly in the amount of $ 0.07 million with a final payment of $ 9.4 million at maturity. The 2025 Note is guaranteed by the co-founders of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 million, which are being amortized over the term of the loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of December 31, 2022, the remaining principal payments for the 2025 Note, are as follows (in thousands Interest expense associated with the 2025 Note was $ 0.4 million and $ 0.4 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, accrued interest of less than $ 0.1 million was included in accrued expenses and other liabilities in the accompanying consolidated balance sheets. Note Payable—Paycheck Protection Program The Company applied for and received a loan, which is in the form of a note dated May 5, 2020, from HSBC Bank USA, National Association (“HSBC”) in the aggregate amount of approximately $ 0.3 million (the “PPP Loan”), pursuant to the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. As of December 31, 2021, there were no events of default under the PPP Loan. The Company paid off the PPP Loan in full, including all accrued but unpaid interest to the repayment date, in August 2021. Promissory Note with Related Party In October 2022, the Company entered into a related party unsecured promissory note (the “2022 Promissory Note”) with UBI for $ 4.2 million. The 2022 Promissory Note accrues interest at 7.0 % per annum and is due October 1, 2026 . The 2022 Promissory Note was issued to satisfy accounts payable to UBI totaling $ 4.2 million. As of December 31, 2022 the outstanding principal under the 2022 Promissory Note was $ 4.2 million. During the year ended December 31, 2022 the Company incurred less than $ 0.1 million in interest expense and no interest was paid related to the Promissory Note. The carrying value of the 2022 Promissory Note is as follows (in thousands): As of December 31, 2022, the remaining principal payments for the 2022 Promissory Note, are as follows (in thousands): 2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2020 $ 2,100 $ 194 $ 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ — December 31, 2022 2021 Principal $ 10,455 $ 10,883 Unamortized debt issuance cost (131) (184) Carrying amount 10,324 10,699 Less: current portion (391) (376) Note payable, net of current portion and debt issuance cost $ 9,933 $ 10,323 Amount 2023 $ 444 2024 458 2025 9,553 $ 10,455 December 31, 2022 Principal $ 4,225 Less: current portion (1,113) Note payable, net of current portion $ 3,112 Amount 2023 $ 1,113 2024 1,029 2025 1,103 2026 980 $ 4,225

Convertible Preferred Stock	12 Months Ended
Convertible Preferred Stock	Dec. 31, 2022
Convertible Preferred Stock [Abstract]
Convertible Preferred Stock	11. Convertible Preferred Stock In connection with the Reorganization, each UNS convertible preferred share was exchanged for 0.2191 shares of Vaxxinity preferred stock and each share of COVAXX convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity preferred stock. During the first and second quarters of 2021, the Company raised gross proceeds of $ 122.8 million in connection with its Series B preferred stock financing. The Company issued a total of 15,365,574 shares at a price of $ 8.00 per share. All shares of the Company’s Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering. As of December 31, 2022 and 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 50,000,000 shares of preferred stock with a par value of $ 0.0001 per share. There were no shares of preferred stock outstanding as of December 31, 2022 and 2021. The table below details the Company's Class A common stock which was issued upon conversion of Series A and Series B preferred stock concurrently with the closing of the IPO in November 2021. The common stock issued upon conversion reflects the application of the stock split described in Note 1. As of December 31, 2021 Issuance Dates Shares Issued and Outstanding Prior to IPO Class A Common Stock Issued Upon IPO Conversion Series A preferred stock March 2021 62,223,095 39,989,083 Series B preferred stock March 2021 5,441,863 3,497,338 Series B preferred stock June 2021 9,923,711 6,377,699 77,588,669 49,864,120

Simple Agreement for Future Equity-SAFE	12 Months Ended
Simple Agreement for Future Equity-SAFE	Dec. 31, 2022
Simple Agreement for Future Equity-SAFE [Abstract]
Simple Agreement for Future Equity-SAFE	12. Simple Agreement for Future Equity—SAFE During the years ended December 31, 2021 and 2020, the Company executed SAFE arrangements. The SAFEs were not mandatorily redeemable, nor did they require the Company to repurchase a fixed number of shares. The Company determined that the SAFEs contained a liquidity event provision that embodied an obligation indexed to the fair value of the Company’s equity shares and could require the Company to settle the SAFE obligation by transferring assets or cash. For this reason, the Company recorded the SAFEs as a liability under ASC 480 and re-measured the fair value at the end of each reporting period, with changes in fair value reported in earnings. In March 2020, the Company issued a SAFE (“SAFE 1”) for $ 0.4 million, which converted into 463,162 shares of Series Seed-2 convertible preferred stock at $ 0.7773 per share in April 2020. In June, July, and August 2020, the Company issued a series of SAFEs (“SAFE 2”) for $ 14.7 million, which converted into 6,307,690 shares of Series A-2 convertible preferred stock (“Series A-2 preferred”) at $ 2.3241 per share in August 2020. The Company determined the fair value of the SAFE 2 investment on the date of conversion and recognized the difference between the fair value on the date of conversion and the initial fair value of SAFE 2 investment in the consolidated statements of operations. In December 2020, the Company issued a series of SAFEs (collectively, “SAFE 3”) for $ 24.3 million. In January 2021, the Company issued additional SAFEs for $ 2.9 million which had the same terms as SAFE 3. Key provisions of SAFE 3 are as follows: Equity Financing —Upon initial closing of a qualified financing of at least $ 50.0 million, SAFE 3 will automatically convert into the greater of (1) the number of shares of SAFE 3 preferred stock equal to the purchase amount divided by the SAFE 3 price, defined as the price per share equal to the post-money valuation divided by all shares outstanding, all convertible securities, all issued, outstanding and promised options, and the unissued option pool, or (2) the number of shares of SAFE 3 preferred stock equal to the purchase amount divided by the discount price, defined as the price per share of the standard preferred stock sold in a qualified financing multiplied by eighty percent (80%). Liquidity Event —If there is a liquidity event, as defined, before the termination of SAFE 3, SAFE 3 will automatically be entitled to receive a portion of proceeds, subject to the liquidation priority set forth in the agreement, due and payable immediately prior to, or concurrent with, the consummation of such liquidity event, equal to the greater of (i) the purchase amount or (ii) the amount payable on the number of shares of common stock equal to the purchase amount divided by the liquidity price, as outlined in the agreements. Dissolution Event —If there is a dissolution event, as described in the agreements, before the termination of SAFE 3, the investor will automatically be entitled, subject to the liquidation priority set forth in the agreement, to receive a portion of proceeds equal to the purchase amount, due and payable to the investor immediately prior to the consummation of the dissolution event. Termination —SAFE 3 will automatically terminate immediately following the earliest to occur of: (i) the issuance of capital stock to the investor pursuant to the automatic conversion provisions of SAFE 3 or (ii) the payment, or setting aside for payment, of amounts due the investor. In connection with the Contribution and Exchange Agreement, the holders of SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of Vaxxinity’s preferred stock. The SAFEs were converted into shares of the Company’s Series A preferred stock pursuant to the Contribution and Exchange Agreement. Prior to the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of the Company’s Series A preferred stock, which were converted into Series A Common Stock in connection with the Company’s IPO.

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2022
Common Stock [Abstract]
Common Stock	13. Common Stock As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021, all outstanding shares of common stock of UNS and COVAXX were contributed to Vaxxinity and exchanged for an aggregate of 60,360,523 shares of Vaxxinity’s Class A common stock and 10,999,149 shares of Vaxxinity’s Class B common stock. Each UNS share of common stock was exchanged for 0.2191 shares of Vaxxinity common stock and each share of COVAXX common stock was exchanged for 3.4233 shares of Vaxxinity common stock. In June 2021, the Company converted 2,874,983 shares of Class A common stock held by the Company’s Chief Executive Officer and Executive Chairman on a one-to-one basis for shares of Class B common stock. Vaxxinity’s Amended and Restated Certificate of Incorporation dated November 15, 2021 authorized 1,100,000,000 shares of common stock with a par value of $ 0.0001 per share, of which 1,000,000,000 shares have been designated as Class A common stock and 100,000,000 shares have been designated as Class B common stock. Holders of Class A common stock and Class B common stock have identical rights, except with respect to voting and conversion. Except as otherwise expressly provided in Vaxxinity’s Amended and Restated Certificate of Incorporation or Bylaws, or required by applicable law, holders of Class A common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders and holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of stockholders, except (i) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation that alter or change the powers, preferences or special rights of a class of capital stock in a manner that affects its holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are entitled to receive, ratably, dividends as may be declared by Vaxxinity’s board of directors out of funds legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, dividend, and liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of Vaxxinity’s preferred stock. The Company has reserved shares of common stock for issuance for the following purposes: December 31, 2022 2021 Options and RSU issued and outstanding 20,716,760 21,387,909 Options available for future grants 6,064,003 7,209,538 Warrants issued and outstanding 1,928,020 1,928,020 28,708,783 30,525,467

Equity Incentive Plan	12 Months Ended
Equity Incentive Plan	Dec. 31, 2022
Equity Incentive Plan [Abstract]
Equity Incentive Plan	14. Equity Incentive Plan Stock Options In March 2021, the Company replaced the 2017 and 2020 Stock Option and Grant Plans with the 2021 Stock Option and Grant Plan (the “Existing 2021 Plan”), which provided for the Company to grant qualified incentive options, nonqualified options, restricted stock awards, unrestricted stock awards, and restricted stock units to employees and non-employees to purchase the Company’s Class A common stock. The Existing 2021 Plan authorized the issuance of up to 21,593,830 shares of Class A common stock pursuant to awards. In August 2021, the Company canceled existing options to purchase, in aggregate, 6,362,455 shares of Class A common stock in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. In November 2021, the Company replaced the Existing 2021 Plan with the 2021 Omnibus Incentive Compensation Plan (the “New 2021 Plan”), which provides for the Company to grant nonqualified stock options, incentive (qualified) stock options, stock appreciation rights, restricted share awards, restricted stock units, performance awards, cash incentive awards and other equity-based awards (including fully vested shares). The New 2021 Plan replaced the Existing 2021 Plan and no further grants will be made under the Existing 2021 Plan. The following is a summary of certain terms and conditions of the New 2021 Plan. At its inception in November 2021, the maximum number of shares of common stock that could be issued under the New 2021 Plan was 8,700,000 shares of Class A equity. This number increases automatically on January 1 of each year, commencing January 1, 2023, by the number of shares equal to the lesser of (i) 4 % of the outstanding shares of the Company’s common stock on the immediately preceding December 31, (ii) the number of shares determined by the Compensation Committee, if any such determination is made, and (iii) the number of shares underlying any awards granted during the preceding calendar year, net of the shares underlying awards canceled or forfeited under the New 2021 Plan. On January 1, 2023, in accordance with the automatic “evergreen” provision of the New 2021 Plan, the maximum number of shares that can be issued under the plan was increased to 11,886,306 . As of December 31, 2022, 6,064,003 shares were available for future grant. Shares issued under the New 2021 Plan that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock, withheld to cover the exercise price or tax withholdings, or otherwise terminated, other than by exercise, shall be added back to the shares available for issuance under the New 2021 Plan. The exercise price for grants made pursuant to the terms of the New 2021 Plan is determined in the applicable grant by the board of directors. Any incentive options granted to persons possessing less than 10% of the total combined voting power of all classes of stock may not have an exercise price of less than 100% of the fair market value of the common stock on the grant date. Any incentive options granted to persons possessing more than 10% of the total combined voting power of all classes of stock may not have an exercise price of less than 110% of the fair market value of the common stock on the grant date. The option term for incentive awards may not be greater than ten years from the date of the grant. Incentive options granted to persons possessing more than 10% of the total combined voting power of all classes of stock may not have an option term of greater than five years from the date of the grant. The vesting period for equity-based awards is determined at the discretion of the board of directors. As of December 31, 2022 there were options to purchase 14,054,305 shares of Class A common stock outstanding and options to purchase 6,362,455 shares of Class B common stock outstanding, of which 9,830,751 Class A and 4,968,437 Class B shares, respectively were exercisable. Stock Option Activity The following table summarizes stock option activity for the year ended December 31, 2022: The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock. The intrinsic value of options exercised during each of the years ended December 31, 2022 and 2021 was $ 4.5 million and less than $ 0.1 million, respectively. The weighted-average grant-date fair value per share of options granted during the years ended December 31, 2022 and 2021 was $ 2.21 and $ 4.21 , respectively. The total fair value of options vested during the years ended December 31, 2022 and 2021 was $ 8.8 million and $ 24.5 million, respectively. Valuation of Stock Options Granted that Contain Service Conditions Only The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the assumptions noted in the table below for those options granted in the years ended December 31, 2022 and 2021: In August 2021, the Company canceled 378,786 existing Class A common stock options with service-based conditions held by Mei Mei Hu in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. There was no incremental stock-based compensation expense as a result of this modification as the fair- value-based measures of the modified award immediately after the modification were less than the fair-value-based measures of the original award immediately before the modification. Stock Options Granted to Employees that Contain Performance and Market Conditions Included in the stock options granted during the year ended December 31, 2021 were stock options to purchase 6,799,625 shares of Class A common stock that contain performance- and market-based vesting conditions granted to the Mei Mei Hu, Louis Reese, and Peter Diamandis. In August 2021, the stock option awards for the Mei Mei Hu and Louis Reese totaling 5,983,670 shares were cancelled in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. The fair value of the awards granted to Mei Mei Hu and Louis Reese at the modification date was $ 23.8 million, valued using the Monte-Carlo simulation model. The assumptions used in the Monte-Carlo simulation model were as follows: The stock option awards for Peter Diamandis totaling 815,955 shares had a grant date fair value of $ 0.3 million. The assumptions used in the Monte-Carlo simulation model were as follows: The compensation expense for these awards is recognized when the vesting condition is met for the performance-based criteria, and over the derived service period for the market-based criteria. The condition for the performance-based criteria in the stock options was based on the Company's completion of its IPO, and the condition for the market-based criteria in the stock options was based on the future price of the Company's common stock trading at or above a specified threshold. During the year ended December 31, 2021, stock options for an aggregate of 5,439,700 of the total 6,799,625 shares containing performance- and market-based vesting conditions were vested following the satisfaction of the performance-based condition achieved through the Company’s completion of its IPO. As of December 31, 2022, the market-based vesting conditions had not been achieved. Restricted Stock The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2022: The aggregate fair value of restricted stock that vested was less than $ 0.1 million for the year ended December 31, 2021. No restricted stock vested during the year ended December 31, 2022. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations (in thousands): As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 16.2 million, which is expected to be recognized over a weighted average period of 2.7 years. December 31, 2022 2021 Risk-free interest rate 1.46 % - 4.22 % 0.59 % - 1.35 % Expected term (in years) 5.5 - 6.1 5.0 - 6.3 Expected volatility 90.01 % - 97.82 % 71.6 % - 93.4 % Expected dividend yield 0.00 % 0.00 % Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 1,387,221 2.96 Exercised (1,066,586) (3.26) Forfeited (1,291,784) (7.14) Balance at December 31, 2022 20,416,760 $ 5.07 6.8 $ 7,166 Options vested and exercisable at December 31, 2022 14,799,188 $ 4.62 6.5 $ 6,923 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at December 31, 2022 300,000 $ 3.76 Years Ended December 31, 2022 2021 Research and development $ 3,276 $ 1,343 General and administrative 5,438 29,069 Total stock-based compensation expense $ 8,714 $ 30,412 Time to expiration (in years) 4.5 Volatility 75 % Risk-free interest rate 58 % Cost of equity 25 % Fair value of underlying common stock (as of valuation date) $ 10.07 Time to expiration (in years) 1 Volatility 90 % Risk-free interest rate 0.09 % Cost of equity 25 % Fair value of underlying common stock (as of valuation date) $ 4.12

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Taxes [Abstract]
Income Taxes	15. Income Taxes The sources of losses from continuing operations, before income taxes, classified between domestic entities and those entities domiciled outside of the U.S., are as follows (in thousands): Tax Expense (Benefit) The components of the provision for income taxes are as follows for the years ended December 31, 2022 and 2021 (in thousands): Tax Rate Reconciliation The Company’s effective tax rate for the years ended December 31, 2022 and 2021 was 0.00 % and 0.00 %, respectively. A reconciliation of the provision for income taxes at the statutory rate to the amount reflected in the consolidated statements of operations is as follows (in thousands): Deferred Tax Assets (Liabilities) The Company computes income taxes using the liability method. This method requires recognition of deferred tax assets and liabilities, measured by enacted rates, attributable to temporary differences between the financial statements and the income tax basis of assets and liabilities. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that certain deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those specific jurisdictions prior to the dates on which such net operating losses expire. The Company maintained a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021 because the Company has determined that it is more likely than not that these assets will not be fully realized based on a current evaluation of expected future taxable income and the Company is in a cumulative loss position. The valuation allowance increased by $ 15.0 million during the year ended December 31, 2022 and $ 20.9 million during the year ended December 31, 2021, primarily as a result of net operating losses generated during the periods. The Company reevaluates the positive and negative evidence at each reporting period. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): Net Operating Losses The Company had total net operating loss carryforwards for U.S. federal income tax purposes of $ 165.1 million, and $ 134.6 million as of December 31, 2022 and 2021, respectively, that have no expiration date and foreign net operating loss carryforwards of $ 29.2 million and $ 24.0 million, respectively, that have no expiration date. Utilization of the NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code Sections 382 and 383 (the “Code”), as amended, and similar state provisions. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future. If the Company experienced an ownership change at any time since its formation, utilization of the NOL or tax credit carryforwards to offset future taxable income and taxes, respectively, would be subject to annual limitation under the Code. The annual limitation may result in the expiration of the NOL and credits before utilization. If impaired, the NOL and credit carryforwards would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. On March 27, 2020, the President of the United States signed into law the CARES Act, which, along with earlier issued IRS guidance, contains numerous provisions that may benefit the Company, including the deferral of certain taxes. The CARES Act did not have a material impact on the Company’s tax provision for the years ended December 31, 2022 and 2021. The Consolidated Appropriations Act, 2021, which was enacted on December 27, 2020, has expanded, extended, and clarified selected CARES Act provisions, specifically on Paycheck Protection Program loan and Employee Retention Tax Credit, 100% deductibility of business meals as well as other tax extenders. The Consolidated Appropriations Act did not have a material impact on the Company’s tax provision for the year ended December 31, 2022 and 2021. The Inflation Reduction Act (IRA) was signed into law on August 16, 2022. The IRA introduces a 15% corporate alternative minimum tax (CAMT) for corporations whose average annual adjusted financial statement income (AFSI) for any consecutive three-tax-year period ending after December 31, 2021 and preceding the tax year exceeds $1.0 billion and a 1% excise tax on stock repurchases made by publicly traded U.S. corporations. Since the Company does not meet the book income threshold to be subject to CAMT, the excise tax is not an ASC 740 tax, they are not expected to have any impact. The other tax law updates are not expected to have any material impact to the Company's consolidated financial statements and related disclosures. The CHIPS and Science Act was signed into law on August 9, 2022. The Act introduces the advanced manufacturing investment tax credit, a 25% tax credit for investments in semiconductor manufacturing. It also includes incentives for manufacturing semiconductors, as well as specialized tooling equipment required in the semiconductor manufacturing process. The Company is not currently claiming any such tax credits, as such the tax law updates are not expected to have any material impact to the Company's consolidated financial statements and related disclosures. Enacted in 2017, the Tax Cuts and Jobs Act (“TCJA”) included significant changes in tax law including a change to Internal Revenue Code section 174 regarding the deductibility of research and experimentation expenses (“R&E expenses”). The section 174 tax law change had a delayed effective date and became effective for the Company in 2022. New section 174 requires that companies capitalize and amortize R&E expenses performed in the U.S. over five years and further provides for a fifteen-year amortization period for R&E expenses incurred outside the U.S. The Company has factored any impact of section 174 in the Company’s consolidated financial statements and related disclosures. The Company is subject to tax in the United States and many state and local jurisdictions. The Company, with certain exceptions, is subject to income tax examinations by U.S. federal, state and local for tax years 2017 and future periods. The Company is not currently under audit for any US federal or state or foreign income tax audits. Uncertain Tax Positions A summary of the Company’s unrecognized tax benefits activity and related information is presented as follows (in thousands): The unrecognized tax benefits for U.S. jurisdiction of $ 0.7 million, if recognized, would not have an impact on the Company’s effective tax rate assuming the Company continues to maintain a full valuation allowance position against its U.S. deferred tax assets. The remaining unrecognized tax benefits of less than $ 0.1 million, if recognized, will have an impact on the effective tax rate. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. We accrued $ 0.2 million in interest and penalties related to prior year’s tax filings, as of December 31, 2022. The Company is subject to U.S. federal income tax as well as income tax of various foreign jurisdictions. Generally, the statute of limitations for examination of the Company’s U.S. federal and foreign income tax filings are open for the years ending December 31, 2017 and future periods. Years Ended December 31, Losses before taxes 2022 2021 Domestic entities $ (69,943) $ (128,538) Entities outside the U.S. (5,477) (8,636) $ (75,420) $ (137,174) Years Ended December 31, 2022 2021 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — — Provision for income taxes $ — $ — Years Ended December 31, 2022 2021 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit (1.17) % 0.50 % Stock compensation (0.68) % (3.65) % Foreign rate differential (0.59) % (0.74) % Uncertain tax positions 0.0 % 0.0 % Other 1.41 % (1.90) % Change in valuation allowance (19.98) % (15.21) % Provision for income taxes 0.0 % 0.0 % As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 39,184 $ 32,405 Stock Compensation 2,090 1,735 Section 174 Costs 7,424 — Other 559 27 Total deferred tax assets 49,257 34,167 Less: valuation allowance (49,173) (34,106) Net deferred tax assets $ 84 $ 61 Deferred tax liabilities: Depreciation $ (84) $ (61) Net deferred tax liabilities (84) (61) Net deferred income taxes $ — $ — Years Ended December 31, 2022 2021 Uncertain tax position liability at the beginning of the year $ 652 $ 652 Increases (decreases) related to tax positions taken during current period — — Uncertain tax position liability at the end of the year $ 652 $ 652

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2022
Net Loss Per Share [Abstract]
Net Loss Per Share	16. Net Loss Per Share The Company’s unvested restricted common shares have been excluded from the computation of basic net loss per share. The Company’s potentially dilutive securities, which include options, unvested restricted stock, convertible notes payable and convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the years ended December 31, 2022 and 2021 because including them would have had an anti-dilutive effect: December 31, 2022 2021 Unvested restricted stock 300,000 - Options issued and outstanding 20,416,760 21,387,909 Warrants issued and outstanding 1,928,020 1,928,020 22,644,780 23,315,929

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies Contractual Obligations The Company enters into agreements with contract research organizations (“CROs”) to conduct clinical trials and preclinical studies and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of December 31, 2022, the Company had remaining prepayments to CROs of $ 2.9 million and remaining prepayments to CMOs of less than $ 0.1 million for activities associated with the conduct of its clinical trials and for the production of the Company’s product candidates. Michael J. Fox Foundation Grant On November 3, 2021, the Company was awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) in the amount of $ 0.8 million to be used in a project for the exploration of markers for target engagement in individuals immunized with UB-312, an active a -Synuclein immunotherapy. The Company will oversee sample management, sample preparation (IgG fractions) and distribution, as well as characterize the binding properties of the antibodies against pathological forms of aSyn. As funding is expected to be utilized over a two-year period, as cash is received, the amount expected to the utilized within twelve months is recognized to short-term restricted cash/deposits, with a corresponding short-term accrued liability, which is released as the related expenses are offset. The Company recognizes payments from MJFF as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. The remaining balance of cash received is recognized to long-term restricted cash/deposits, with a corresponding long-term accrued liability. As of December 31, 2022, there was no balance remaining in the accrued liability related to this grant. For the years ended December 31, 2022 and 2021, the Company recognized $ 0.1 million and less than $ 0.1 million, respectively, as a reduction of research and development expenses for amounts reimbursed through the grant. Coalition for Epidemic Preparedness Innovations (“CEPI”) Grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI has agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in 2022, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. The Company will also be performing further manufacturing scale-up work to enable readiness for potential commercialization. Under the terms of the agreement with CEPI, if successful, a portion of the released doses of the commercial product will be delivered to the COVID-19 Vaccines Global Access (“COVAX”) consortium for distribution to developing countries at low cost. Cash payments received in advance under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. As funding is expected to be received in tranches over an eighteen month period, and the amounts received in each tranche are expected to the utilized within twelve months, the funds received are reflected within restricted cash with a corresponding short-term accrued liability. The Company recognizes payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. As of December 31, 2022, the balance of the restricted cash and short-term accrued liability was $ 1.0 million. For the year ended December 31, 2022, the Company recognized a reduction of $ 7.5 million of research and development expenses. Lease Agreements The Company has two operating lease agreements for office and laboratory space. The Company is also required to pay certain operating costs under its leases. In August 2022, the Company entered into a lease for 9,839 square feet of lab and office space with Space Florida in Exploration Park, Florida commencing August 12, 2022. The lease has an initial one-year term with an annual lease obligation of $ 0.5 million, after Lessee credits. Additionally, the lease requires the Company to provide a security deposit in the amount of less than $ 0.1 million. In April 2022, the Company entered into a facility lease agreement for 4,419 square feet of office space in New York, New York. The lease commenced in April 2022 and will expire March 2029 with no option to renew. This lease and its terms were reviewed using the guidance found in ASC 842. Since the lease has a non-cancellable period of one year , and after the first year both the Company and the landlord have the option to early terminate the lease for any or no reason, the Company has elected to apply the short-term expedient, which does not subject the New York lease to capitalization. Rent expense for each of the years ended December 31, 2022 and 2021 amounted to $ 0.5 million and less than $ 0.1 million, respectively. License Agreements In October 2014, the Company entered into a contribution agreement with UBI, whereby UBI contributed and assigned to the Company assets and granted a non-exclusive license to certain technologies deemed necessary or reasonably useful in the utilization of the licensed intellectual property. In consideration, the Company issued 32,505,306 shares of common stock to UBI. The agreement allowed for exploitation of all diagnostic, prophylactic, and therapeutic uses and indications in humans in the field of neurology. The agreement was amended in August 2019 to provide the Company with exclusivity (except as to UBI) in the field of neurology and the flexibility to pursue indications outside the initial field limitations. In connection with the amendment, the Company agreed to execute an exclusive, worldwide license agreement for any product that is developed by the Company outside the original field. The terms and conditions are to be negotiated in good faith and mutually agreed upon. The Company anticipates that if it is required to enter into an exclusive license agreement, it will be able to negotiate financial terms for the license at prevailing market rates within the pharmaceutical industry. Accordingly, the Company may be required to pay UBI upfront fees, revenue royalties, development milestones, commercial milestones, sublicense fees, and other related fees. Vaxxinity’s COVAXX subsidiary was formed in March 2020 through a transfer of technology from UBI, UBI IP Holdings, and UBI US Holdings, LLC, all related parties of the Company, whereby the Company, pursuant to an April 2020 license agreement, obtained exclusive rights to intellectual property and technology related to the discovery of vaccines, diagnostic assays, and antigens for use against all coronaviruses including, without limitation, SARS, MERS, and COVID-19 in all strains in humans. The license is worldwide, perpetual, exclusive and fully paid-up. There are no future royalty or milestone payment obligations associated with the agreement. The Company has the right to grant sublicenses. The Company considered ASC 805, “Business Combinations” and ASC 730, “Research and Development” in determining how to account for the issuance of common stock. The license agreement is considered to be a common control transfer; however, the related party did not have any basis in the assets licensed, so there was no accounting impact for the Company. In August 2021, Vaxxinity entered into a license agreement (the “Platform License Agreement”) with UBI and certain of its affiliates that expanded intellectual property rights previously licensed under previously issued license agreements with UBI. As part of the agreement, Vaxxinity obtained a worldwide, sublicensable (subject to certain conditions), perpetual, fully paid-up, royalty-free license to research, develop, make, have made, utilize, import, export, market, distribute, offer for sale, sell, have sold, commercialize or otherwise exploit peptide-based vaccines in the field of all human prophylactic and therapeutic uses, except for such vaccines related to human immunodeficiency virus (HIV), herpes simplex virus (HSE) and Immunoglobulin E (IgE). The patents and patent applications licensed under the Platform License Agreement include claims directed to a CpG delivery system, artificial T helper cell epitopes and certain designer peptides and proteins utilized in UB-612. As described above, in consideration for the Platform License Agreement, the Company issued to UBI a warrant to purchase Class A common stock (the “UBI Warrant”). The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, “Research and Development” (“ASC 730”) in determining how to account for the issuance of the Class A common stock warrants. The Class A common stock warrants were issued to a related party in exchange for a license agreement. The majority of the voting interests in the related party and that of the Company were held by a group of immediate family members, at the time of the transaction, and as such the transaction constitutes a common control transaction, which requires the license to be accounted for at the carrying value in the books of the transferor. As the related party did not have any basis in the assets licensed, there was no accounting impact for the Company. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has not accrued any liabilities related to such obligations as of December 31, 2022 or 2021. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of December 31, 2022 and 2021, the Company was not a party to any material legal matters or claims. In December 2022, the Board became aware of pending litigation filed by the Company’s CEO against a significant stockholder, Ask America, LLC (“Ask America”). The CEO filed the lawsuit in Texas in May 2022 regarding an alleged private agreement between the CEO, the Company’s Chairman, and Ask America, relating to the potential purchase of stock by Ask America in the Company’s November 2021 initial public offering, on behalf of a former director. Ask America asserts that the CEO and Chairman guaranteed a loan by Ask America to fund the former director’s contemplated purchase. The lawsuit seeks a declaration that no enforceable transaction was ever completed or consummated. Although the Company is not a party to the litigation, the Board formed a special committee, comprised of independent directors who are being advised by independent legal counsel, to conduct an investigation into the circumstances of the litigation and the purported transaction. The investigation concluded in the first quarter of 2023, and the company is evaluating certain additional control measures, including (i) additional training for executives and directors on securities regulations, (ii) additional internal reporting requirements regarding transactions between Company insiders, stockholders, or other related parties, and (iii) retention of a consultant or other advisor with public company and capital markets experience to assist management in connection with capital markets strategy and activity. Loss Contingency In April 2021, the Company engaged United Biopharma, Inc. (UBP) to begin acquiring raw materials for use in the production of GMP grade recombinant protein for UB-612, our Covid vaccine candidate. It was anticipated that $ 7.2 million in raw materials would be needed to produce the initial 30kg of protein. An Authorization to Proceed (ATP) agreement authorized UBP to acquire the first $ 3 million of materials using an advance payment from Vaxxinity, pending execution of a final supply agreement between the parties. Through August 2021, $ 7.2 million of materials were ordered, $ 3 million of materials were received by UBP and paid for with the advance payment, and the Company expensed $ 1.2 million as these raw materials were used to produce proteins. During 2022, Vaxxinity recognized an additional $ 1.8 million in expense related to the materials UBP had taken possession of but had not yet used in production. When Vaxxinity asked to pause further manufacture of protein upon rejection of the EUA by Taiwan in August 2021, UBP requested that its suppliers cancel the remaining $ 4.2 million in orders where it had not taken possession of the materials. In the fourth quarter of 2022, the Company learned that most of the suppliers refused to cancel the orders, although some agreed to seek other buyers for the materials. For these orders, management has not yet concluded that a loss for Vaxxinity for this entire amount is probable, since they were not originally authorized by the ATP, and UBP’s suppliers may be able to dispose of some amount to other buyers. Hence, an expense has not been recognized for them.

Benefit Plans	12 Months Ended
Benefit Plans	Dec. 31, 2022
Benefit Plans [Abstract]
Benefit Plans	18. Benefit Plans In March 2018, the Company established a defined contribution savings plan under Section 401(k) of the Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company does not make matching contributions to the Plan. The Company offers its Ireland-based employees a Personal Retirement Savings Account (“PRSA”) that allows participants to defer a portion of their annual compensation. The Company provides contributions equal to 5 % of each participant’s annual salary. During the years ended December 31, 2022 and 2021, the Company contributed less than $ 0.1 million per year to the PRSA accounts.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	19. Related Party Transactions The Company has a Related Party policy which defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Audit Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders. The Company has related party arrangements with UBI and a number of its affiliated companies listed namely, United Biomedical, Inc., Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, Inc (“UBP”) and UBI IP Holding (“UBI-IP”). As of December 31, 2022 UBI and its affiliated companies owned 44 % of the Company’s stock. The majority of the voting interests in both UBI and the Company were held by a group of immediate family members , and as such the entities are under common control. These related parties are governed by various Master Services Agreement s (“MSA”) detailed below. UBI MSA - UBI provides research, development and clinical functions to the Company. There is also a purchase arrangement with UBI for the production and shipment of the Company’s diagnostic test kits. UBIA MSA - UBI-Asia for manufacturing, quality control, testing, validation, and supply services. UBP MSA - United BioPharma, Inc provide the Company with manufacturing, testing and validation. COVID MSA (“COVID MSA”) - COVID MSA provides that UBI acts as COVAXX’s agent with respect to matters relating the Company’s COVID-19 program and provides research, development, manufacturing and back office administrative services to the Company. COVID-19 Relief MSA - A four-company MSA with UBI, UBI-Asia and UBP. The Company is an exclusive licensee of technologies related to diagnostics, vaccines, and therapies for COVID-19. The MSA established the terms under which UBI-Asia provides research, development, testing and manufacturing services to the Company and UBP provides contract development and manufacturing services to the Company. Total amounts due to related parties were $ 12.8 million and $ 19.4 million as of December 31, 2022 and 2021, respectively. Total amounts due from related parties were $ 0.4 million and $ 0.4 million as of December 31, 2022 and 2021, respectively. Total service fees incurred were $ 4.2 million and $ 35.4 million for the years ended December 31, 2022 and 2021, respectively. Taiwan Centers for Disease Control Grant (“Taiwan CDC”) UBI-Asia, which is responsible for applying for and managing grants on our behalf under the COVID-19 program, was awarded a grant by the Taiwan CDC for COVID-19 vaccine development. The Company contracted with UBI-Asia to conduct a two-phase clinical trial of a COVID-19 vaccine candidate in Taiwan, which was completed in 2021. Costs that were incurred to complete the two phases of the clinical trial were reimbursed based on the achievement of certain milestones as provided in the agreement. Total related party operating activity, including the activity described above is as follows (in thousands): December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 237 $ 3,517 Property and equipment, net — 337 Amounts due from related parties 414 393 Liabilities Accrued expenses — — Amounts due to related parties 12,772 19,407 Current portion of note payable 1,113 — Note payable 3,112 — Accrued interest payable $ 73 $ — Years Ended December 31, 2022 2021 Consolidated statements of operations Revenue $ — $ — Cost of revenue — — Operating expenses Research and development Services provided by related parties 4,172 41,430 Taiwan CDC grant reimbursement from related party — (7,199) General and administrative Services provided by related parties — 1,173 Other (income) expense Related party interest expense $ 73 $ —

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events On March 9, 2023, the Company completed its rolling submission of a conditional authorization application to the UK MHRA for UB- 612 based on the Phase 3 study results.

Summary of Significant Accounting Policies (Policy)	12 Months Ended
Summary of Significant Accounting Policies (Policy)	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial reporting. The consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement and the Stock Split ratio.
Foreign currency translation	Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Income statement accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency (losses) gains in the consolidated statements of operations.
Segment information	Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment.
Use of estimates	Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common stock and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, prepaid expense recognition, income tax valuation allowance and the accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions.
Related party transaction	Related party transactions The Company has a policy governing related party transactions that defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Audit Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Audit Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return.
Restricted cash	Restricted cash As of December 31, 2022 and 2021 a deposit of $ 1.1 million and $ 0.2 million, respectively, was restricted from withdrawal. These restrictions related to cash payments received in advance under the CEPI Funding Agreement and securing credit card obligations as of December 31, 2022 and securing credit card obligations as of December 31, 2021. These balances are included in restricted cash on the accompanying consolidated balance sheets.
Short term investments	Short Term Investments The Company determines the appropriate classification of its investments at the time of purchase. Currently, all of the Company’s investments are classified as available-for-sale in accordance with ASC Topic 320. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income or loss. Realized gains and losses, interest income earned on the Company’s cash, cash equivalents and investments, and amortization or accretion of discounts and premiums on investments are included within other income (expense) on the accompanying consolidated statements of operations. Available-for-sale debt securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported within equity as accumulated other comprehensive income on the accompanying consolidated statement of stockholder’s equity (deficit). The Company did no t record any such impairments during the year ended December 31, 2022 and 2021.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in money market accounts. The Company maintains each of its cash balances with high- quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers.
Leases	Leases At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in Operating lease right-of-use assets and Operating lease liabilities in our consolidated balance sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. The Company has elected to apply the practical short-term expedient to leases with a lease term of 12 months or less, which does not subject the leases to capitalization.
Property and equipment	Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term
Impairment of long-lived assets	Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets.
Deferred offering costs	Deferred offering costs The Company capitalizes certain legal, audit, accounting and other third-party fees that are directly associated with an in-process capital financing effort as deferred offering costs until such financing is consummated. After consummation of the financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the financing. Should the financing be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the accompanying consolidated statements of operations. Fair value measurements Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Prior to the conversion in accordance with the Contribution and Exchange Agreement, the majority of the Company’s convertible notes and all of the simple agreement for future equity (“SAFE”) and warrant liabilities were carried at fair value and were classified as Level 3 liabilities. Convertible notes payable The Company issued convertible notes payable at various times from 2014 to 2021. The Company accounts for the convertible notes payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are accounted for as straight debt under ASC 470, Debt (“ASC 470”). The Company has elected to separate interest expense from the full change in fair value of the convertible notes. Debt issuance costs incurred by the Company are amortized to interest expense over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations. On March 2, 2021, each convertible note that was outstanding was exchanged for shares of Series A preferred stock (see Note 9). Debt issuance costs The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statements of operations. Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, each SAFE that was outstanding was converted into shares of the Company’s Series A preferred stock (see Note 12). Classification of convertible preferred stock The Company records all convertible preferred stock at its original issuance price, less direct and incremental issuance costs, as stipulated by its terms. The Company’s convertible preferred stock is classified outside of stockholders’ deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. All shares of the Company’s Series A and Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering (see Note 11).
Fair value measurements	Fair value measurements Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Prior to the conversion in accordance with the Contribution and Exchange Agreement, the majority of the Company’s convertible notes and all of the simple agreement for future equity (“SAFE”) and warrant liabilities were carried at fair value and were classified as Level 3 liabilities.
Convertible notes payable	Convertible notes payable The Company issued convertible notes payable at various times from 2014 to 2021. The Company accounts for the convertible notes payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are accounted for as straight debt under ASC 470, Debt (“ASC 470”). The Company has elected to separate interest expense from the full change in fair value of the convertible notes. Debt issuance costs incurred by the Company are amortized to interest expense over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations. On March 2, 2021, each convertible note that was outstanding was exchanged for shares of Series A preferred stock (see Note 9).
Debt issuance costs	Debt issuance costs The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statements of operations.
Simple agreement for future equity - SAFE	Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, each SAFE that was outstanding was converted into shares of the Company’s Series A preferred stock (see Note 12).
Classification of convertible preferred stock	Classification of convertible preferred stock The Company records all convertible preferred stock at its original issuance price, less direct and incremental issuance costs, as stipulated by its terms. The Company’s convertible preferred stock is classified outside of stockholders’ deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. All shares of the Company’s Series A and Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering (see Note 11).
Revenue recognition	Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. The Company applies ASC 606 to contracts with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by evaluating whether each promised good or service is distinct. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services, the intended benefit of the contract and whether each good or service is separately identifiable from the other aspects of the contractual relationship. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the transaction price to be constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and, if over time, recognition is based on the use of an output or input method. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer.
Coalition for epidemic preparedness grant	Coalition for Epidemic Preparedness (“CEPI”) grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI has agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in early 2022, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. Cash payments received in advance under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. As funds are received they are included within restricted cash offset by a corresponding short-term accrued liability. The Company recognizes payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred.
Taiwan centers for disease control grant	Taiwan Centers for Disease Control grant United Biomedical, Inc., Asia (“UBI-Asia”), a related party through common ownership which is responsible for applying for and managing grants on the Company’s behalf, was awarded a grant by the Taiwan Centers for Disease Control (“Taiwan CDC”) for COVID-19 vaccine development. UBI-Asia contracted with the Company to conduct a two-phase clinical trial of a COVID-19 vaccine candidate in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as defined in the agreement. At each reporting date, the Company assesses the status of all the activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the Taiwan CDC to reimburse costs incurred on the clinical trials and not expected to be refunded back to the Taiwan CDC as contra research and development expenses in the accompanying consolidated statements of operations.
Research and development	Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 19). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent costs	Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-based compensation	Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model (“Black-Scholes”), which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. The Company, both prior to and after the IPO in November 2021, lacks sufficient company-specific historical and implied volatility information for its stock, and therefore estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The conditions present in the Company's grants contain both performance and market conditions. The effect of each condition is reflected in the grant-date fair value and the performance-based options are measured considering the probability of satisfying the performance and market conditions. The Company has used a Monte Carlo Simulation Model to calculate the fair value of the performance condition (the completion of the IPO) and market condition (the 25% higher value after the IPO condition). The performance condition was determined to not be probable at the time of the grant date, and the recognition of compensation cost was deferred until the IPO was consummated in November 2021. The recognition of expense for the portion of the grant-date fair value assigned to the market condition will be recognized as expense according to the derived service period in the valuation model.
Income taxes	Income taxes The Company accounts for income taxes according to the ASC 740, Income Taxes (“ASC 740”) using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax positions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net loss per share	Net loss per share Basic earnings per common share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income (loss) by the weighted- average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. For purpose of this calculation, outstanding options, unvested restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share if their effect is anti-dilutive. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive.
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, as long as the Company remains an EGC, it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs.
Reclassifications	Reclassifications The Company reclassified certain prepaid expenses from prepaid materials and supplies to clinical prepayments within the consolidated balance sheet to provide more current information on the components of this account. Prior year amounts have been reclassified to conform to the current year presentation. Additionally, certain expenses were reclassified between the research and development and general and administrative expenses within the consolidated statements of operations. These changes have no impact on our previously reported consolidated net loss, financial position or net increase in cash, cash equivalents, and restricted cash. Prior year amounts were not reclassified to conform to the current year presentation in the consolidated statements of operations.
Recently issued accounting pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
Recently adopted accounting standards	Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018- 11provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company did not enter into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Useful life of property and equipment	Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term

Short-Term Investments (Tables)	12 Months Ended
Short-Term Investments (Tables)	Dec. 31, 2022
Short Term Investments [Abstract]
Short-Term Investments	As of December 31, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 53,549 $ (197) $ 53,352 Total $ 53,549 $ (197) $ 53,352

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 53,352 $ — $ — $ 53,352 Money market account 27,724 — — 27,724 Total assets $ 81,076 $ — $ — $ 81,076
Schedule of Carrying Amounts and Estimated Fair Values of Financial Instruments	Convertible Notes Balance at December 31, 2020 $ 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545) Balance at December 31, 2021 $ —
Schedule of Activity in Level 3	SAFE Liability Balance at December 31, 2020 $ 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Balance at December 31, 2021 $ — Warrant Liability Balance at December 31, 2020 $ 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614) Balance at December 31, 2021 $ —

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	December 31, 2022 2021 Clinical prepayments $ 2,679 $ 612 Prepaid insurance 1,870 3,510 Prepaid materials and supplies 248 3,517 Deposits 232 869 Other 522 343 $ 5,551 $ 8,851

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2022
Property and Equipment, Net [Abstract]
Property and Equipment, Net	December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 3,146 1,831 Leasehold improvements 403 — Software 415 168 Facilities, furniture and fixtures 37 85 Vehicles 87 87 Construction in progress 65 199 Total property and equipment 16,136 14,353 Less: accumulated depreciation (3,624) (1,981) Property and equipment, net $ 12,512 $ 12,372

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	December 31, 2022 2021 Accrued external research and development $ 6,904 $ 1,501 Accrued bonuses 2,568 2,294 Accrued professional fees and other 1,722 692 Accrued interest 176 32 $ 11,370 $ 4,519

Other Long-Term Liabilities (Tables)	12 Months Ended
Other Long-Term Liabilities (Tables)	Dec. 31, 2022
Other Liabilities [Abstract]
Other Liabilities	December 31, 2022 2021 Accrued tax provision $ 236 $ 236 Accrued rent — 1 $ 236 $ 237

Convertible Notes Payable (Tables)	12 Months Ended
Convertible Notes Payable (Tables)	Dec. 31, 2022
Convertible Notes Payable [Abstract]
Convertible Notes	Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2020 $ 7,710 $ 10,510 $ 1,972 $ 3,848 $ 674 $ 183 $ (217) $ — $ 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

Notes Payable (Tables)	12 Months Ended
Notes Payable (Tables)	Dec. 31, 2022
2018 Related Notes and 2019 Executive Note [Member]
Debt Instrument [Line Items]
Schedule Of Notes Payable	2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2020 $ 2,100 $ 194 $ 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ —
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Schedule Of Notes Payable	December 31, 2022 2021 Principal $ 10,455 $ 10,883 Unamortized debt issuance cost (131) (184) Carrying amount 10,324 10,699 Less: current portion (391) (376) Note payable, net of current portion and debt issuance cost $ 9,933 $ 10,323
Schedule of Maturities of Notes Payable	Amount 2023 $ 444 2024 458 2025 9,553 $ 10,455
Promissory Note with Related Party [Member]
Debt Instrument [Line Items]
Schedule Of Notes Payable	December 31, 2022 Principal $ 4,225 Less: current portion (1,113) Note payable, net of current portion $ 3,112
Schedule of Maturities of Notes Payable	Amount 2023 $ 1,113 2024 1,029 2025 1,103 2026 980 $ 4,225

Convertible Preferred Stock (Tables)	12 Months Ended
Convertible Preferred Stock (Tables)	Dec. 31, 2022
Convertible Preferred Stock [Abstract]
Schedule of preferred stock	As of December 31, 2021 Issuance Dates Shares Issued and Outstanding Prior to IPO Class A Common Stock Issued Upon IPO Conversion Series A preferred stock March 2021 62,223,095 39,989,083 Series B preferred stock March 2021 5,441,863 3,497,338 Series B preferred stock June 2021 9,923,711 6,377,699 77,588,669 49,864,120

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2022
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	December 31, 2022 2021 Options and RSU issued and outstanding 20,716,760 21,387,909 Options available for future grants 6,064,003 7,209,538 Warrants issued and outstanding 1,928,020 1,928,020 28,708,783 30,525,467

Equity Incentive Plans (Tables)	12 Months Ended
Equity Incentive Plans (Tables)	Dec. 31, 2022
Equity Incentive Plan [Abstract]
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 1,387,221 2.96 Exercised (1,066,586) (3.26) Forfeited (1,291,784) (7.14) Balance at December 31, 2022 20,416,760 $ 5.07 6.8 $ 7,166 Options vested and exercisable at December 31, 2022 14,799,188 $ 4.62 6.5 $ 6,923
Weighted Average Assumptions	December 31, 2022 2021 Risk-free interest rate 1.46 % - 4.22 % 0.59 % - 1.35 % Expected term (in years) 5.5 - 6.1 5.0 - 6.3 Expected volatility 90.01 % - 97.82 % 71.6 % - 93.4 % Expected dividend yield 0.00 % 0.00 % Time to expiration (in years) 4.5 Volatility 75 % Risk-free interest rate 58 % Cost of equity 25 % Fair value of underlying common stock (as of valuation date) $ 10.07 Time to expiration (in years) 1 Volatility 90 % Risk-free interest rate 0.09 % Cost of equity 25 % Fair value of underlying common stock (as of valuation date) $ 4.12
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at December 31, 2022 300,000 $ 3.76
Schedule of Stock-Based Compensation Expense for Stock Options	Years Ended December 31, 2022 2021 Research and development $ 3,276 $ 1,343 General and administrative 5,438 29,069 Total stock-based compensation expense $ 8,714 $ 30,412

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Taxes [Abstract]
Schedule of Loss Before Income Taxes	Years Ended December 31, Losses before taxes 2022 2021 Domestic entities $ (69,943) $ (128,538) Entities outside the U.S. (5,477) (8,636) $ (75,420) $ (137,174)
Schedule of Income Tax Expense	Years Ended December 31, 2022 2021 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — — Provision for income taxes $ — $ —
Reconciliation of Income Tax Percent	Years Ended December 31, 2022 2021 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit (1.17) % 0.50 % Stock compensation (0.68) % (3.65) % Foreign rate differential (0.59) % (0.74) % Uncertain tax positions 0.0 % 0.0 % Other 1.41 % (1.90) % Change in valuation allowance (19.98) % (15.21) % Provision for income taxes 0.0 % 0.0 %
Schedule of Deferred Tax Assets	As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 39,184 $ 32,405 Stock Compensation 2,090 1,735 Section 174 Costs 7,424 — Other 559 27 Total deferred tax assets 49,257 34,167 Less: valuation allowance (49,173) (34,106) Net deferred tax assets $ 84 $ 61 Deferred tax liabilities: Depreciation $ (84) $ (61) Net deferred tax liabilities (84) (61) Net deferred income taxes $ — $ —
Schedule of Unrecognized Tax Benefits	Years Ended December 31, 2022 2021 Uncertain tax position liability at the beginning of the year $ 652 $ 652 Increases (decreases) related to tax positions taken during current period — — Uncertain tax position liability at the end of the year $ 652 $ 652

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2022
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	December 31, 2022 2021 Unvested restricted stock 300,000 - Options issued and outstanding 20,416,760 21,387,909 Warrants issued and outstanding 1,928,020 1,928,020 22,644,780 23,315,929

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 237 $ 3,517 Property and equipment, net — 337 Amounts due from related parties 414 393 Liabilities Accrued expenses — — Amounts due to related parties 12,772 19,407 Current portion of note payable 1,113 — Note payable 3,112 — Accrued interest payable $ 73 $ — Years Ended December 31, 2022 2021 Consolidated statements of operations Revenue $ — $ — Cost of revenue — — Operating expenses Research and development Services provided by related parties 4,172 41,430 Taiwan CDC grant reimbursement from related party — (7,199) General and administrative Services provided by related parties — 1,173 Other (income) expense Related party interest expense $ 73 $ —

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)
Nature of Business Disclosures [Line Items]
Proceeds from issuance of simple agreement for future equity	$ 0	$ 2,900
Repayment of convertible notes	$ 0	2,000
Issuance of stock, shares \| shares	32,505,306
Cash and cash equivalents	$ 33,475	144,885
Net Income Loss	(75,222)	(137,175)
Accumulated deficit	$ (304,703)	(229,481)
Reverse stock split	1.556
Net Cash Provided By Used In Operating Activities	$ (55,928)	(80,990)
Highly Liquid Assets	87,900
Short Term Investments	53,352	0
Restricted cash	1,095	$ 172
Restricted for the reimbursement of certain research and development expenses	$ 1,000
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares	6,000,000
Share Price \| $ / shares	$ 13.00
Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares	900,000
Underwriters [Member] \| Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares	537,711
Share Price \| $ / shares	$ 71.1
UNS. [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio	0.2191
COVAXX [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio	3.4233
Debt Conversion Converted Instrument Shares Issued 1 \| shares	4,047,344

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Restricted cash	$ 1,095,000	$ 172,000
Lessee, Lease, Description [Line Items]
Impairment charges	0	$ 0
Funding amount provided	$ 9,300,000

Summary of Significant Accounting Policies (Useful Life of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2022
Airplane [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	Shorter of the useful life of improvement or the remaining lease term

Short Term Investment (Details) $ in Thousands	12 Months Ended
Short Term Investment (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Cash And Cash Equivalents [Line Items]
Amortized Cost	$ 53,549
Unrealized Gains (Losses), Net	(197)
Recorded Basis	53,352
U S Treasury Securities [Member]
Cash And Cash Equivalents [Line Items]
Amortized Cost	53,549
Unrealized Gains (Losses), Net	(197)
Recorded Basis	$ 53,352

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Fair value of preferred stock issued on conversion date		$ 35,600,000
Transfer amount between classes	$ 0	$ 0
Series A-1 Preferred [Member]
Class Of Warrant Or Right [Line Items]
Number of shares available to purchase from vested warrants			205,970
Warrants, exercise price			$ 0.003
Warrant, contractual term			10 years
Number of warrants exercised			71,862
Cash proceeds from warrants exercised			$ 1,000,000
Warrant outstanding			134,106

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 27,724
Liabilities	81,076
Short-term investments	53,352	$ 0
Cash and cash equivalents	33,475	144,885
Assets	81,076	139,794
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	27,724	139,794
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	27,724
Liabilities	81,076
Short-term investments	53,352
Assets	81,076	139,794
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	27,724	139,794
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	0
Short-term investments	0
Assets	0	0
Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	0
Short-term investments	0
Assets	0	0
Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 0	$ 0

Fair Value Measurements (Schedule of Activity in Level 3, Convertible Notes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from issuance of convertible note payable	$ 0	$ 2,000
Repayment of convertible notes	0	(2,000)
Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	0	24,680
Balance		0
Convertible Debt [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 0	24,680
Proceeds from issuance of convertible note payable		2,000
Repayment of convertible notes		(2,000)
Debt, Change In Fair Value		2,667
Payments Of Debt Issuance Costs		217
Amortization Of Financing Costs And Discounts		168
Interest On Convertible Debt Net Of Tax		(187)
Debt, Conversion Of Debt Fair Value		(27,545)
Balance		$ 0

Fair Value Measurements (Schedule of Activity in Level 3, SAFE Arrangements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	$ 0	$ (8,365)
Level 3 [Member] \| SAFE Arrangements [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 0	24,335
Change in fair value		8,365
Issuance of SAFEs		2,900
Conversion to Series A-1 convertible preferred stock		(35,600)
Balance		$ 0

Fair Value Measurements (Schedule of Activity in Level 3, Warrants) (Details) - Level 3 [Member] - Warrants [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 400
Change in fair value	214
Conversion Of Warrants	(614)
Balance	$ 0

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Line Items]
Prepaid materials and supplies	$ 248	$ 3,517
Paid in advance to clinical research organizations expenses	1,900
Prepaid Insurance	1,870	3,510
Other prepaid expenses and current assets consist of various sales tax credits and receivables	300	300
Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Prepaid materials and supplies	200	3,500
Unamortized Portion D&O Insurance Fee [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Prepaid Insurance	$ 1,600	$ 3,300

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Clinical prepayments	$ 2,679	$ 612
Prepaid Insurance	1,870	3,510
Prepaid materials and supplies	248	3,517
Deposits	232	869
Other	522	343
Total	$ 5,551	$ 8,851

Property and Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation	$ 1,684	$ 1,102

Property and Equipment, Net (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment	$ 16,136	$ 14,353
Less accumulated depreciation	(3,624)	(1,981)
Property and equipment, net	12,512	12,372
Airplane [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,146	1,831
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	403	0
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	415	168
Facilities, Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	37	85
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	87	87
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 65	$ 199

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued external research and development	$ 6,904	$ 1,501
Accrued bonuses	2,568	2,294
Accrued professional fees and other	1,722	692
Accrued interest	176	32
Total	$ 11,370	$ 4,519

Other Long-Term Liabilities (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities [Abstract]
Accrued Payroll Taxes Current And Noncurrent	$ 0.2	$ 0.2
Income Tax Examination Penalties And Interest Accrued	$ 0.2

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities [Abstract]
Accrued tax provision	$ 236	$ 236
Lease liability	0	1
Total	$ 236	$ 237

Convertible Notes Payable (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Proceeds from issuance of convertible note payable	$ 0	$ 2,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Fair value of liability		0	$ 24,680
Settlements		(2,187)
Interest Expense, Debt		200
Change in fair value		$ 2,700
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List	Liabilities Fair Value Adjustment
Convertible Debt [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	4.80%
Convertible Debt [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	6.00%

Convertible Notes Payable (Convertible Notes) (Details) - Convertible Debt [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 24,680
Additions	4,835
Settlements	(2,187)
Amortization	217
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	0
Issuance Costs [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	(217)
Additions	0
Settlements	0
Amortization	217
Conversion of Convertible Notes to Series A preferred stock	0
Balance	0
Conversion to Series A Preferred [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0
Additions	0
Settlements	0
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	(27,545)
Principal Or Proprietary Transactions [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	7,710
Additions	0
Settlements	(2,000)
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(5,710)
Balance	0
Principal Or Proprietary Transactions [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	10,510
Additions	2,000
Settlements	0
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(12,510)
Balance	0
Change In Fair Value [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,972
Additions	812
Settlements	0
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(2,784)
Balance	0
Change In Fair Value [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	3,848
Additions	1,855
Settlements	0
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(5,703)
Balance	0
Interest Expense [Member] \| Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	674
Additions	58
Settlements	(187)
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(545)
Balance	0
Interest Expense [Member] \| Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	183
Additions	110
Settlements	0
Amortization	0
Conversion of Convertible Notes to Series A preferred stock	(293)
Balance	$ 0

Notes payable (Narrative) (Details) - USD ($)	12 Months Ended
Notes payable (Narrative) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
2018 Related Notes and Reorg. Convertible Notes [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties					$ 2,000,000.0
Debt Instrument Interest Rate Stated Percentage					5.00%
Interest Expense, Debt		$ 100,000
2019 Executive Note [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties				$ 100,000
Debt Instrument Interest Rate Stated Percentage				5.00%
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties			$ 11,500,000
Debt Instrument Interest Rate Stated Percentage			3.40%
Interest Expense, Debt	$ 400,000	$ 400,000
Debt Instrument Periodic Payment Interest			$ 70,000.00
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid			9,400,000
Payments Of Debt Issuance Costs			$ 300,000
Debt Instrument Increase Accrued Interest	100,000
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	300,000
Promissory Note with Related Party [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	4,200,000
Proceeds from issuance of convertible notes payable with related parties	$ 4,200,000
Debt Instrument Interest Rate Stated Percentage	7.00%
Debt maturity date	Oct. 01, 2026
Interest Expense, Debt	$ 0
Debt Instrument Increase Accrued Interest	$ 100,000

Notes payable (Notes payable with related parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Repayments of note payable with related party	$ (430)	$ (414)
2018 Related Notes and 2019 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance	0	2,294
Debt Instrument Increase Accrued Interest		19
Repayments of note payable with related party		(100)
Interest paid		(8)
Conversion		(2,205)
Ending balance		0
Principal Amount [Member] \| 2018 Related Notes and 2019 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance	0	2,100
Debt Instrument Increase Accrued Interest		0
Repayments of note payable with related party		(100)
Interest paid		0
Conversion		(2,000)
Ending balance		0
Accrued Interest [Member] \| 2018 Related Notes and 2019 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance	$ 0	194
Debt Instrument Increase Accrued Interest		19
Repayments of note payable with related party		0
Interest paid		(8)
Conversion		(205)
Ending balance		$ 0

Notes payable (Carrying Value) (Details) - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Note, 2025 [Member]
Debt Instrument [Line Items]
Principal	$ 10,455	$ 10,883
Unamortized debt issuance cost	131	184
Total	10,324	10,699
Less: current portion	(391)	(376)
Note payable, net of current portion and debt issuance cost	9,933	$ 10,323
Promissory Note with Related Party [Member]
Debt Instrument [Line Items]
Principal	4,225
Less: current portion	(1,113)
Note payable, net of current portion and debt issuance cost	$ 3,112

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Notes payable (Annual Principal Payments) (Details) - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Note, 2025 [Member]
Debt Instrument [Line Items]
2023	$ 444
2024	458
2025	9,553
Total	10,455	$ 10,883
Promissory Note with Related Party [Member]
Debt Instrument [Line Items]
2023	1,113
2024	1,029
2025	1,103
2026	980
Total	$ 4,225

Convertible Preferred Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Nov. 14, 2021	Aug. 31, 2020
Class Of Stock [Line Items]
Proceeds from Issuance Initial Public Offering	$ 0	$ 71,077
Preferred stock, shares authorized/designated	50,000,000	50,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, share outstanding	0	0	77,588,669
Safe 2 [Member]
Class Of Stock [Line Items]
Share Price				$ 2.3241
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding			62,223,095
Amended Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued	15,365,574
Proceeds from Issuance Initial Public Offering	$ 122,800
Share Price	$ 8.00
Convertible Preferred Stock Shares Issued Upon Conversion	3.4233
Preferred stock, shares authorized/designated	50,000,000
Preferred stock, par value	$ 0.0001
Amended Preferred Stock [Member] \| COVAXX [Member]
Class Of Stock [Line Items]
Convertible Preferred Stock Shares Issued Upon Conversion	0.2191

Convertible Preferred Stock (Schedule of Preferred Stock) (Details) - shares	Dec. 31, 2022	Dec. 31, 2021	Nov. 14, 2021
Class Of Stock [Line Items]
Preferred stock, share outstanding	0	0	77,588,669
Common Stock Issuable Upon Conversion	49,864,120
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding			62,223,095
Common Stock Issuable Upon Conversion	39,989,083
Series B Preferred Stock Issued March 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding			9,923,711
Common Stock Issuable Upon Conversion	6,377,699
Series B Preferred Stock Issued June 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding			5,441,863
Common Stock Issuable Upon Conversion	3,497,338

Simple Agreement for Future Equity-SAFE (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2020	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Simple Agreement for Future Equity [Line Items]
Shares issued			32,505,306
Loss on fair value of investment			$ 0	$ (8,365)
Proceeds from issuance of simple agreement for future equity			0	2,900
SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity		$ 400
SAFE 2 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity	$ 14,700
Shares issued	6,307,690
Share Price	$ 2.3241
SAFE 3 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity				$ 2,900	$ 24,300
Minimum value of qualified financing, equity financing provision			$ 50,000
Series Seed-2 Stock [Member] \| SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Shares issued		463,162
Share Price		$ 0.7773

Common Stock (Narrative) (Details) - $ / shares	12 Months Ended
Common Stock (Narrative) (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Issuance of stock, shares	32,505,306
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,000,000
Share Price	$ 13.00
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Class A Common Stock [Member] \| Chief Executive Officer [Member]
Class Of Stock [Line Items]
Shares converted	2,874,983
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares		6,537,711
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,100,000,000
Common stock, par value	$ 0.0001
Amended And Restated Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,000,000,000
Amended And Restated Common Stock [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000
UNS [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	60,360,523
Shares converted	0.2191
UNS [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	10,999,149
Shares converted	3.4233

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Options issued and outstanding	20,416,760	21,387,909
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding	20,716,760	21,387,909
Options available for future grants	6,064,003	7,209,538
Warrants issued and outstanding to purchase shares of common stock	1,928,020	1,928,020
Reserved Shares of Common Stock	28,708,783	30,525,467

Equity Incentive Plan (Narrative) (Details - USD ($)	1 Months Ended	12 Months Ended
Equity Incentive Plan (Narrative) (Details - USD ($)	Aug. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding		20,416,760	21,387,909
Options exercisable		14,799,188
Total stock-based compensation expense		$ 8,714,000	$ 30,412,000
Shares canceled		1,291,784
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant		6,064,003	7,209,538
Options outstanding		20,716,760	21,387,909
Minimum [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period		1 year
Employee and Non-Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period		4 years
Class A Common Stock [Member] \| Co-Founder [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares canceled	378,786
2021 Stock Option and Grant Plan [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options exercised		$ 4,500,000
Weighted-average grant-date fair value per share of options granted		$ 2.21	$ 4.21
Total fair value of options vested		$ 8,800,000	$ 24,500,000
2021 Stock Option and Grant Plan [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost		$ 16,200,000
Recognized over a weighted average period		2 years 8 months 12 days
2021 Stock Option and Grant Plan [Member] \| Maximum [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options exercised			100,000
2021 Stock Option and Grant Plan [Member] \| First Anniversary [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested		$ 0	$ 100,000
2021 Stock Option and Grant Plan [Member] \| Performance And Market Based [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant			6,799,625
Shares vested			5,439,700
2021 Stock Option and Grant Plan [Member] \| Board of Directors [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable		815,955
Intrinsic value of options exercised		$ 300,000
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan		21,593,830
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan		8,700,000
Increase in number of shares available for grant		11,886,306
Number of shares available for grant		6,064,003
Options outstanding		14,054,305
Options exercisable		9,830,751
Percent of shares outstanding increase, in certain scenarios		4.00%
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable			6,799,625
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant		6,362,455
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding		6,362,455
Options exercisable		4,968,437
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	5,983,670
Total fair value of options vested	$ 23,800,000

Equity Incentive Plan (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity Incentive Plan [Abstract]
Number of Stock Options Outstanding, Balance at December 31, 2021	21,387,909
Number of Stock Options Outstanding, Granted	1,387,221
Number of Stock Options Outstanding, Exercised	(1,066,586)
Number of Stock Options Outstanding, Forfeited	(1,291,784)
Number of Stock Options Outstanding, Balance at December 31, 2022	20,416,760	21,387,909
Number of Stock Options Outstanding, Options vested and exercisable at December 31, 2022	14,799,188
Weighted Price Per Share, Balance at December 31, 2021	$ 5.25
Weighted Price Per Share, Granted	2.96
Weighted Price Per Share, Exercised	(3.26)
Weighted Price Per Share, Forfeited	(7.14)
Weighted Price Per Share, Balance at December 31, 2021	5.07	$ 5.25
Weighted Price Per Share, Options vested and exercisable at December 31, 2022	$ 4.62
Weighted Contractual Term (years), Balance at December 31	6 years 9 months 18 days	7 years 4 months 24 days
Weighted Contractual Term (years), Options vested and exercisable at December 31, 2022	6 years 6 months
Aggregate Intrinsic Value, Balance at December 31	$ 7,166	$ 49,684
Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2022	$ 6,923

Equity Incentive Plan (Weighted Average Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.46%	0.59%
Risk-free interest rate, maximum	4.22%	1.35%
Expected volatility, minimum	90.01%	71.60%
Expected volatility, maximum	97.82%	93.40%
Expected dividend yield	0.00%	0.00%
Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	58.00%
Expected term (in years)	4 years 6 months
Expected volatility	75.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 10.07
Peter Diamandis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.09%
Expected term (in years)	1 year
Expected volatility	90.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 4.12
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 6 months	5 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days	6 years 3 months 18 days

Equity Incentive Plan (Summary of Restricted Stock Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested at December 31, 2021 \| shares	0
Number of Shares, Issued \| shares	300,000
Number of Shares, Unvested at December 31, 2022 \| shares	300,000
Weighted Average Grant Date Fair Value Per Share, Unvested at December 31, 2021 \| $ / shares	$ 0
Weighted Average Grant Date Fair Value Per Share, Issued \| $ / shares	3.76
Weighted Average Grant Date Fair Value Per Share, Unvested at December 31, 2022 \| $ / shares	$ 3.76

Equity Incentive Plan (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 8,714	$ 30,412
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	3,276	1,343
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 5,438	$ 29,069

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Valuation allowance increase	$ 15.0	$ 20.9
Unrecognized tax benefits that would impact effective tax rate	$ 0.1
Effective Income Tax Rate Continuing Operations	0.00%	0.00%
Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate	$ 0.7
Income Tax Examination Penalties And Interest Accrued	0.2
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	165.1	$ 134.6
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 29.2	$ 24.0

Income Taxes (Schedule of Loss Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Abstract]
Domestic entities	$ (69,943)	$ (128,538)
Entities outside the U.S.	(5,477)	(8,636)
Loss before income taxes	$ (75,420)	$ (137,174)

Income Taxes (Schedule of Income Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 0	$ 0
State and local	0	0
Foreign	0	0
Total current tax expense	0	0
Deferred tax (benefit):
Federal	0	0
State and local	0	0
Foreign	0	0
Total deferred tax (benefit)	0	0
Provision for income taxes	$ 0	$ 0

Income Taxes (Reconciliation of Income Tax Percent) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Abstract]
Income taxes at statutory rate	21.00%	21.00%
State and local taxes, net of federal benefits	(1.17%)	0.50%
Stock compensation	(0.68%)	(3.65%)
Foreign rate differential	(0.59%)	(0.74%)
Uncertain tax positions	0.00%	0.00%
Other	1.41%	(1.90%)
Change in valuation allowance	(19.98%)	(15.21%)
Provision for income taxes	0.00%	0.00%

Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Abstract]
Net operating loss carryforwards	$ 39,184	$ 32,405
Stock Compensation	2,090	1,735
Section 174 Costs	7,424	0
Other	559	27
Total deferred tax assets	49,257	34,167
Less: valuation allowance	(49,173)	(34,106)
Net deferred tax assets	84	61
Depreciation	(84)	(61)
Net deferred tax liabilities	(84)	(61)
Net deferred income taxes	$ 0	$ 0

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Abstract]
Uncertain tax position liability at the beginning of the year	$ 652	$ 652
Increases (decreases) related to tax positions taken during current period	0	0
Uncertain tax position liability at the end of the year	$ 652	$ 652

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	22,644,780	23,315,929
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	300,000	0
Options Issued And Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	20,416,760	21,387,909
Warrants Issued And Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,928,020	1,928,020

Commitments and Contingencies (Narrative) (Details)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Narrative) (Details)	Apr. 30, 2021 USD ($)	Dec. 31, 2022 USD ($) ft² Item shares	Dec. 31, 2021 USD ($)
Commitments And Contingencies [Line Items]
Rent expense		$ 500,000	$ 100,000
Shares issued \| shares		32,505,306
Restricted Cash And Current Accrued Liability		$ 1,000,000.0
Reduction In Research And Development		$ 7,500,000
Number of Operating Lease Agreements \| Item		2
Project Grant		$ 800,000
Grant, Accrued Liability, Current		0
Grant, Decrease In Research And Development		100,000	$ 100,000
Exploration Park, Florida [Member]
Commitments And Contingencies [Line Items]
Security deposit		$ 100,000
Lease in square feet \| ft²		9,839
Lease, initial term		1 year
Lease obligation		$ 500,000
New York, New York [Member]
Commitments And Contingencies [Line Items]
Lease in square feet \| ft²		4,419
Lease, initial term		1 year
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments		$ 2,900,000
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments		100,000
UB-612 [Member]
Commitments And Contingencies [Line Items]
Project Grant		9,300,000
Materials Ordered	$ 7,200,000
Materials Expensed	1,200,000	$ 1,800,000
Materials Received	3,000,000
Anticipated raw material amount	7,200,000
Value of materials authorized using advance payment	3,000,000
Amount of material canceled	$ 4,200,000

Benefit Plans (Narrative) (Details) - Foreign Plan [Member] - Personal Retirement Savings Account [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan Disclosure [Line Items]
Company contribution percent	5.00%
Company contributions	$ 0.1	$ 0.1

Related Party Transactions (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Due to related parties	$ 12.8	$ 19.4
Service fees	4.2	35.4
Due From Related Parties	$ 0.4	$ 0.4
United Biomedical Inc [Member] \| UBI [Member]
Related Party Transaction [Line Items]
Percent of ownership	44.00%

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

+ Details

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

- Definition

Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	$ 5,551	$ 8,851
Property and equipment, net	12,512	12,372
Amounts due from related parties	400	400
Amounts due to related parties	12,800	19,400
Current portion of note payable	1,113	0
Note payable	3,112	0
Revenue	0	66
Cost of revenue	0	1,937
Other (income) expense	(757)	12,100
UBI IP [Member] \| Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	237	3,517
Property and equipment, net	0	337
Amounts due from related parties	414	393
Accrued expenses	0	0
Amounts due to related parties	12,772	19,407
Current portion of note payable	1,113	0
Note payable	3,112	0
Accrued interest payable	73	0
Revenue	0	0
Cost of revenue	0	0
Research and development	4,172	41,430
General and administrative	0	1,173
Other (income) expense	73	0
UBI IP [Member] \| Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Research and development	$ 0	$ (7,199)